

DOI	Model	Objective	Type of validation	Population	Start of accrual (year)	End of accrual (year)	End of follow-up (year)	Follow-up (average)	Participant type	Location of centres	Outcome (year-disease)	Parameters
10.1016/j.jhep.2022.02.021	CLiVD score (non-lab)	D	-	FINRISK and Health 2000	1992	2012	2016	12.9 years	general people	Finland	>10-SLD/advanced liver disease/cirrhosis/liver death	age, WHR, alcohol use (spline variable), diabetes, smoking status, sex*smoking status
	CLiVD score (non-lab)	V	Internal	FINRISK and Health 2000	1992	2012	2016	12.9 years	general people	Finland	>10-SLD/advanced liver disease/cirrhosis/liver death	age, WHR, alcohol use (spline variable), diabetes, smoking status, sex*smoking status
	CLiVD score (lab)	D	-	FINRISK and Health 2000	1992	2012	2016	12.9 years	general people	Finland	>10-SLD/advanced liver disease/cirrhosis/liver death	age, WHR, alcohol use (spline variable), GGT, diabetes, smoking status, sex*GGT, sex*smoking status
	CLiVD score (lab)	V	Internal	FINRISK and Health 2000	1992	2012	2016	12.9 years	general people	Finland	>10-SLD/advanced liver disease/cirrhosis/liver death	age, WHR, alcohol use (spline variable), GGT, diabetes, smoking status, sex*GGT, sex*smoking status
	CLiVD score (non-lab)	V	External	Whitehall II	1997	1999	-	21.6 years	general people	UK	>10-SLD/advanced liver disease/cirrhosis/liver death	age, WHR, alcohol use (spline variable), diabetes, smoking status, sex*smoking status
	CLiVD score (non-lab)	V	External	CCHS cohorts	2001	2002	-	16.0 years	general people	Denmark	>10-SLD/advanced liver disease/cirrhosis/liver death	age, WHR, alcohol use (spline variable), diabetes, smoking status, sex*smoking status
	CLiVD score (lab)	V	External	CCHS cohorts	2001	2002	-	16.0 years	general people	Denmark	>10-SLD/advanced liver disease/cirrhosis/liver death	age, WHR, alcohol use (spline variable), GGT, diabetes, smoking status, sex*GGT, sex*smoking status
	CLiVD score (non-lab)	D	-	FINRISK and Health 2000	1992	2012	2016	12.9 years	general people	Finland	>10-SLD/advanced liver disease/cirrhosis/liver death	age, WHR, alcohol use (spline variable), GGT, diabetes, smoking status, sex*smoking status
	CLiVD score (lab)	D	-	FINRISK and Health 2000	1992	2012	2016	12.9 years	general people	Finland	>10-SLD/advanced liver disease/cirrhosis/liver death	age, WHR, alcohol use (spline variable), GGT, diabetes, smoking status, sex*GGT, sex*smoking status
	CLiVD score (non-lab)	D	-	FINRISK and Health 2000	1992	2012	2016	12.9 years	general people	Finland	>10-SLD/advanced liver disease/cirrhosis/liver death	age, WHR, alcohol use (spline variable), GGT, diabetes, smoking status, sex*smoking status
	CLiVD score (lab)	D	-	FINRISK and Health 2000	1992	2012	2016	12.9 years	general people	Finland	>10-SLD/advanced liver disease/cirrhosis/liver death	age, WHR, alcohol use (spline variable), GGT, diabetes, smoking status, sex*GGT, sex*smoking status
FIB-4	V	External	FINRISK	1992	2012	2016	12.9 years	general people	Finland	>10-SLD/advanced liver disease/cirrhosis/liver death	age, AST, ALT, and PLT	
APRI	V	External	FINRISK	1992	2012	2016	12.9 years	general people	Finland	>10-SLD/advanced liver disease/cirrhosis/liver death	AST, platelet count	
10.1200/jco.2009.26.2675	Won-2010	D	-	Hepatology Clinic at Prince of Wales Hospital (Hong Kong, China), cohort	1997	2000	-	9.94 years	HBV infected	Hong Kong	10-HCC/PLC/liver cancer	age, albumin, bilirubin, HBV DNA, cirrhosis
	Won-2010	V	Internal	Hepatology Clinic at Prince of Wales Hospital (Hong Kong, China), cohort 2	1997	2000	-	10.53 years	HBV infected	Hong Kong	5-HCC/PLC/liver cancer	age, albumin, bilirubin, HBV DNA, cirrhosis
	Won-2010	V	Internal	Hepatology Clinic at Prince of Wales Hospital (Hong Kong, China), cohort 2	1997	2000	-	10.53 years	HBV infected	Hong Kong	10-HCC/PLC/liver cancer	age, albumin, bilirubin, HBV DNA, cirrhosis
	Won-2010	V	Internal	Hepatology Clinic at Prince of Wales Hospital (Hong Kong, China), cohort 2	1997	2000	-	10.53 years	HBV infected	Hong Kong	10-HCC/PLC/liver cancer	age, albumin, bilirubin, HBV DNA, cirrhosis
10.1200/jco.2009.27.4456	Model 1- regression model	D	-	REVEAL-HBV	1991	1992	-	-	HBV infected	Taiwan	5-HCC/PLC/liver cancer	sex, age in 5-year increments, family history of hepatocellular carcinoma, and serum ALT level, HBeAg serostatus
	Model 1- regression model	V	Internal	REVEAL-HBV	1991	1992	-	-	HBV infected	Taiwan	5-HCC/PLC/liver cancer	sex, age in 5-year increments, family history of hepatocellular carcinoma, and serum ALT level, HBeAg serostatus
	Model 1- regression model	D	-	REVEAL-HBV	1991	1992	-	-	HBV infected	Taiwan	10-HCC/PLC/liver cancer	sex, age in 5-year increments, family history of hepatocellular carcinoma, and serum ALT level, HBeAg serostatus
	Model 1- regression model	V	Internal	REVEAL-HBV	1991	1992	-	-	HBV infected	Taiwan	10-HCC/PLC/liver cancer	sex, age in 5-year increments, family history of hepatocellular carcinoma, and serum ALT level, HBeAg serostatus
	Model 2-regression model	D	-	REVEAL-HBV	1991	1992	-	-	HBV infected	Taiwan	5-HCC/PLC/liver cancer	sex, age in 5-year increments, family history of hepatocellular carcinoma, and serum ALT level, a combined variable comprising HBeAg and serum HBV DNA level
	Model 2-regression model	V	Internal	REVEAL-HBV	1991	1992	-	-	HBV infected	Taiwan	5-HCC/PLC/liver cancer	sex, age in 5-year increments, family history of hepatocellular carcinoma, and serum ALT level, a combined variable comprising HBeAg and serum HBV DNA level
	Model 2-regression model	D	-	REVEAL-HBV	1991	1992	-	-	HBV infected	Taiwan	10-HCC/PLC/liver cancer	sex, age in 5-year increments, family history of hepatocellular carcinoma, and serum ALT level, a combined variable comprising HBeAg and serum HBV DNA level
	Model 2-regression model	V	Internal	REVEAL-HBV	1991	1992	-	-	HBV infected	Taiwan	10-HCC/PLC/liver cancer	sex, age in 5-year increments, family history of hepatocellular carcinoma, and serum ALT level, a combined variable comprising HBeAg and serum HBV DNA level
	Model 3-regression model	D	-	REVEAL-HBV	1991	1992	-	-	HBV infected	Taiwan	5-HCC/PLC/liver cancer	sex, age in 5-year increments, family history of hepatocellular carcinoma, and serum ALT level, a combined variable consisting of HBeAg, serum HBV DNA level, and HBV genotype
	Model 3-regression model	V	Internal	REVEAL-HBV	1991	1992	-	-	HBV infected	Taiwan	5-HCC/PLC/liver cancer	sex, age in 5-year increments, family history of hepatocellular carcinoma, and serum ALT level, a combined variable consisting of HBeAg, serum HBV DNA level, and HBV genotype
	Model 3-regression model	D	-	REVEAL-HBV	1991	1992	-	-	HBV infected	Taiwan	10-HCC/PLC/liver cancer	sex, age in 5-year increments, family history of hepatocellular carcinoma, and serum ALT level, a combined variable consisting of HBeAg, serum HBV DNA level, and HBV genotype
	Model 3-regression model	V	Internal	REVEAL-HBV	1991	1992	-	-	HBV infected	Taiwan	10-HCC/PLC/liver cancer	sex, age in 5-year increments, family history of hepatocellular carcinoma, and serum ALT level, a combined variable consisting of HBeAg, serum HBV DNA level, and HBV genotype
	NGMI-HCC	D	-	REVEAL-HBV	1991	1992	-	-	HBV infected	Taiwan	5-HCC/PLC/liver cancer	sex, age in 5-year increments, family history of hepatocellular carcinoma, and serum ALT level, HBeAg serostatus
	NGMI-HCC	V	Internal	REVEAL-HBV	1991	1992	-	-	HBV infected	Taiwan	5-HCC/PLC/liver cancer	sex, age in 5-year increments, family history of hepatocellular carcinoma, and serum ALT level, HBeAg serostatus
NGMI-HCC	D	-	REVEAL-HBV	1991	1992	-	-	HBV infected	Taiwan	10-HCC/PLC/liver cancer	sex, age in 5-year increments, family history of hepatocellular carcinoma, and serum ALT level, HBeAg serostatus	

	NGM1-HCC	V	Internal	REVEAL-HBV	1991	1992	-	-	HBV infected	Taiwan	10-HCC/PLC/liver cancer	sex, age in 5-year increments, family history of hepatocellular carcinoma, and serum ALT level, HBeAg serostatus
	NGM2-HCC	D	-	REVEAL-HBV	1991	1992	-	-	HBV infected	Taiwan	5-HCC/PLC/liver cancer	sex, age in 5-year increments, family history of hepatocellular carcinoma, and serum ALT level, a combined variable comprising HBeAg and serum HBV DNA level
	NGM2-HCC	V	Internal	REVEAL-HBV	1991	1992	-	-	HBV infected	Taiwan	5-HCC/PLC/liver cancer	sex, age in 5-year increments, family history of hepatocellular carcinoma, and serum ALT level, a combined variable comprising HBeAg and serum HBV DNA level
	NGM2-HCC	D	-	REVEAL-HBV	1991	1992	-	-	HBV infected	Taiwan	10-HCC/PLC/liver cancer	sex, age in 5-year increments, family history of hepatocellular carcinoma, and serum ALT level, a combined variable comprising HBeAg and serum HBV DNA level
	NGM2-HCC	V	Internal	REVEAL-HBV	1991	1992	-	-	HBV infected	Taiwan	10-HCC/PLC/liver cancer	sex, age in 5-year increments, family history of hepatocellular carcinoma, and serum ALT level, a combined variable comprising HBeAg and serum HBV DNA level
	NGM3-HCC	D	-	REVEAL-HBV	1991	1992	-	-	HBV infected	Taiwan	5-HCC/PLC/liver cancer	sex, age in 5-year increments, family history of hepatocellular carcinoma, and serum ALT level, a combined variable consisting of HBeAg, serum HBV DNA level, and HRV genotype
	NGM3-HCC	V	Internal	REVEAL-HBV	1991	1992	-	-	HBV infected	Taiwan	5-HCC/PLC/liver cancer	sex, age in 5-year increments, family history of hepatocellular carcinoma, and serum ALT level, a combined variable consisting of HBeAg, serum HBV DNA level, and HRV genotype
	NGM3-HCC	D	-	REVEAL-HBV	1991	1992	-	-	HBV infected	Taiwan	10-HCC/PLC/liver cancer	sex, age in 5-year increments, family history of hepatocellular carcinoma, and serum ALT level, a combined variable consisting of HBeAg, serum HBV DNA level, and HRV genotype
	NGM3-HCC	V	Internal	REVEAL-HBV	1991	1992	-	-	HBV infected	Taiwan	10-HCC/PLC/liver cancer	sex, age in 5-year increments, family history of hepatocellular carcinoma, and serum ALT level, a combined variable consisting of HBeAg, serum HBV DNA level, and HRV genotype
10.1016/j.jhep.2008.07.023	GAG-HCC	D	-	Queen Mary Hospital, Hong Kong.	1995	2005	-	76.8 months	HBV infected	Hong Kong	5-HCC/PLC/liver cancer	sex, age, HBV DNA levels in copies/mL in log, cirrhosis, core promoter mutations
	GAG-HCC	D	-	Queen Mary Hospital, Hong Kong.	1995	2005	-	76.8 months	HBV infected	Hong Kong	5-HCC/PLC/liver cancer	sex, age, HBV DNA levels in copies/mL in log, cirrhosis, core promoter mutations
	GAG-HCC (non core promoter mutations)	D	-	Queen Mary Hospital, Hong Kong.	1995	2005	-	76.8 months	HBV infected	Hong Kong	10-HCC/PLC/liver cancer	sex, age, HBV DNA levels in copies/mL in log, cirrhosis
	GAG-HCC (non core promoter mutations)	D	-	Queen Mary Hospital, Hong Kong.	1995	2005	-	76.8 months	HBV infected	Hong Kong	10-HCC/PLC/liver cancer	sex, age, HBV DNA levels in copies/mL in log, cirrhosis
10.1016/s1470-2045(11)70077-8	REACH-B	D	-	REVEAL-HBV	1991	1992	-	-	HBV infected	Taiwan	<5-HCC/PLC/liver cancer	sex, age, serum ALT concentration, HBeAg status, serum HBV DNA level (by PCR assay)
	REACH-B	D	-	REVEAL-HBV	1991	1992	-	-	HBV infected	Taiwan	5-HCC/PLC/liver cancer	sex, age, serum ALT concentration, HBeAg status, serum HBV DNA level (by PCR assay)
	REACH-B	D	-	REVEAL-HBV	1991	1992	-	-	HBV infected	Taiwan	10-HCC/PLC/liver cancer	sex, age, serum ALT concentration, HBeAg status, serum HBV DNA level (by PCR assay)
	REACH-B	V	External	hospital-based composite international cohort	-	-	-	-	HBV infected	Hong Kong, Yonsei	<5-HCC/PLC/liver cancer	sex, age, serum ALT concentration, HBeAg status, serum HBV DNA level (by PCR assay)
	REACH-B	V	External	hospital-based composite international cohort	-	-	-	-	HBV infected	Hong Kong, Yonsei	5-HCC/PLC/liver cancer	sex, age, serum ALT concentration, HBeAg status, serum HBV DNA level (by PCR assay)
	REACH-B	V	External	hospital-based composite international cohort	-	-	-	-	HBV infected	Hong Kong, Yonsei	10-HCC/PLC/liver cancer	sex, age, serum ALT concentration, HBeAg status, serum HBV DNA level (by PCR assay)
	REACH-B	V	External	University of Hong Kong (UHK)	-	-	-	6.3 years	HBV infected	Hong Kong	<5-HCC/PLC/liver cancer	sex, age, serum ALT concentration, HBeAg status, serum HBV DNA level (by PCR assay)
	REACH-B	V	External	University of Hong Kong (UHK)	-	-	-	6.3 years	HBV infected	Hong Kong	5-HCC/PLC/liver cancer	sex, age, serum ALT concentration, HBeAg status, serum HBV DNA level (by PCR assay)
	REACH-B	V	External	University of Hong Kong (UHK)	-	-	-	6.3 years	HBV infected	Hong Kong	10-HCC/PLC/liver cancer	sex, age, serum ALT concentration, HBeAg status, serum HBV DNA level (by PCR assay)
	REACH-B	V	External	Chinese University of Hong Kong (CUHK)	-	-	-	9.4 years	HBV infected	Hong Kong	<5-HCC/PLC/liver cancer	sex, age, serum ALT concentration, HBeAg status, serum HBV DNA level (by PCR assay)
	REACH-B	V	External	Chinese University of Hong Kong (CUHK)	-	-	-	9.4 years	HBV infected	Hong Kong	5-HCC/PLC/liver cancer	sex, age, serum ALT concentration, HBeAg status, serum HBV DNA level (by PCR assay)
	REACH-B	V	External	Chinese University of Hong Kong (CUHK)	-	-	-	9.4 years	HBV infected	Hong Kong	10-HCC/PLC/liver cancer	sex, age, serum ALT concentration, HBeAg status, serum HBV DNA level (by PCR assay)
	REACH-B	V	External	Yonsei University Hospital (YUH)	-	-	-	7.0 years	HBV infected	Yonsei	<5-HCC/PLC/liver cancer	sex, age, serum ALT concentration, HBeAg status, serum HBV DNA level (by PCR assay)
REACH-B	V	External	Yonsei University Hospital (YUH)	-	-	-	7.0 years	HBV infected	Yonsei	5-HCC/PLC/liver cancer	sex, age, serum ALT concentration, HBeAg status, serum HBV DNA level (by PCR assay)	
REACH-B	V	External	Yonsei University Hospital (YUH)	-	-	-	7.0 years	HBV infected	Yonsei	10-HCC/PLC/liver cancer	sex, age, serum ALT concentration, HBeAg status, serum HBV DNA level (by PCR assay)	
10.1016/j.jhep.2011.09.011	Kuroski-2012	D	-	Musashino Red Cross Hospital	-	-	-	-	HCV infected	Japan	5-HCC/PLC/liver cancer	age, albumin levels, platelet count
	Kuroski-2012	V	External	patients in University of Yamanashi, Tokyo Medical and Dental University, Osaka University, Osaka City University, Nagoya City University, or Toranomon Hospital.	-	-	-	-	HCV infected	Japan	5-HCC/PLC/liver cancer	age, albumin levels, platelet count

10.1016/j.yjmed.2012.05.017	Kurosaki-2012	D	-	JPHC Study Cohort II	1993	1994	2006	12.6 years	general people	Japan	10-HCC/PLC/liver cancer	age, sex, alcohol consumption, BMI, diabetes, coffee consumption, HBV/HCV infection status.
	Kurosaki-2012	V	Internal	JPHC Study Cohort II	1993	1994	2006	12.6 years	general people	Japan	10-HCC/PLC/liver cancer	age, sex, alcohol consumption, BMI, diabetes, coffee consumption, HBV/HCV infection status.
10.1093/jnci/djs72	Wen 1-2012	D	-	MJ cohort	1994	-	2008	8.5 years	general people	Taiwan	10-HCC/PLC/liver cancer	age, sex, pack-year of smoking, alcohol drinking, physical activity, diabetes
	Wen 2-2012	D	-	MJ cohort	1994	-	2008	8.5 years	general people	Taiwan	10-HCC/PLC/liver cancer	age, sex, AST, ALT
	Wen 3-2012	D	-	MJ cohort	1994	-	2008	8.5 years	general people	Taiwan	10-HCC/PLC/liver cancer	age, sex, pack-year of smoking, alcohol drinking, physical activity, diabetes, AST, and ALT
	Wen 4-2012	D	-	MJ cohort	1994	-	2008	8.5 years	general people	Taiwan	10-HCC/PLC/liver cancer	age, sex, pack-year of smoking, alcohol drinking, physical activity, diabetes, AST, ALT, AFP, and HBV
	Wen 1-2012	V	Internal	MJ cohort	1994	-	2008	8.5 years	general people	Taiwan	10-HCC/PLC/liver cancer	age, sex, pack-year of smoking, alcohol drinking, physical activity, diabetes
	Wen 2-2012	V	Internal	MJ cohort	1994	-	2008	8.5 years	general people	Taiwan	10-HCC/PLC/liver cancer	age, sex, AST, ALT
	Wen 3-2012	V	Internal	MJ cohort	1994	-	2008	8.5 years	general people	Taiwan	10-HCC/PLC/liver cancer	age, sex, pack-year of smoking, alcohol drinking, physical activity, diabetes, AST, and ALT
	Wen 4-2012	V	Internal	MJ cohort	1994	-	2008	8.5 years	general people	Taiwan	10-HCC/PLC/liver cancer	age, sex, pack-year of smoking, alcohol drinking, physical activity, diabetes, AST, ALT, AFP, and HBV
	Wen 1-2012	D+V	-	MJ cohort	1994	-	2008	8.5 years	general people	Taiwan	10-HCC/PLC/liver cancer	age, sex, pack-year of smoking, alcohol drinking, physical activity, diabetes
	Wen 2-2012	D+V	-	MJ cohort	1994	-	2008	8.5 years	general people	Taiwan	10-HCC/PLC/liver cancer	age, sex, AST, ALT
	Wen 3-2012	D+V	-	MJ cohort	1994	-	2008	8.5 years	general people	Taiwan	10-HCC/PLC/liver cancer	age, sex, pack-year of smoking, alcohol drinking, physical activity, diabetes, AST, and ALT
	Wen 4-2012	D+V	-	MJ cohort	1994	-	2008	8.5 years	general people	Taiwan	10-HCC/PLC/liver cancer	age, sex, pack-year of smoking, alcohol drinking, physical activity, diabetes, AST, ALT, AFP, and HBV
	Wen 1'-2012	D	-	MJ cohort	1994	-	2008	8.5 years	general people	Taiwan	10-HCC/PLC/liver cancer	age, sex, pack-year of smoking, alcohol drinking, physical activity, diabetes
	Wen 2'-2012	D	-	MJ cohort	1994	-	2008	8.5 years	general people	Taiwan	10-HCC/PLC/liver cancer	age, sex, AST, ALT
	Wen 3'-2012	D	-	MJ cohort	1994	-	2008	8.5 years	general people	Taiwan	10-HCC/PLC/liver cancer	age, sex, pack-year of smoking, alcohol drinking, physical activity, diabetes, AST, and ALT
	Wen 4'-2012	D	-	MJ cohort	1994	-	2008	8.5 years	general people	Taiwan	10-HCC/PLC/liver cancer	age, sex, pack-year of smoking, alcohol drinking, physical activity, diabetes, AST, ALT, AFP, and HBV
	Wen 5'-2012	D	-	MJ cohort	1994	-	2008	8.5 years	general people	Taiwan	10-HCC/PLC/liver cancer	age, sex, pack-year of smoking, alcohol drinking, physical activity, diabetes, AST, ALT, AFP, HBV and HCV
	Wen 1''-2012	V	Internal	MJ cohort	1994	-	2008	8.5 years	general people	Taiwan	10-HCC/PLC/liver cancer	age, sex, pack-year of smoking, alcohol drinking, physical activity, diabetes
	Wen 2''-2012	V	Internal	MJ cohort	1994	-	2008	8.5 years	general people	Taiwan	10-HCC/PLC/liver cancer	age, sex, AST, ALT
	Wen 3''-2012	V	Internal	MJ cohort	1994	-	2008	8.5 years	general people	Taiwan	10-HCC/PLC/liver cancer	age, sex, pack-year of smoking, alcohol drinking, physical activity, diabetes, AST, and ALT
	Wen 4''-2012	V	Internal	MJ cohort	1994	-	2008	8.5 years	general people	Taiwan	10-HCC/PLC/liver cancer	age, sex, pack-year of smoking, alcohol drinking, physical activity, diabetes, AST, ALT, AFP, and HBV
	Wen 5''-2012	V	Internal	MJ cohort	1994	-	2008	8.5 years	general people	Taiwan	10-HCC/PLC/liver cancer	age, sex, pack-year of smoking, alcohol drinking, physical activity, diabetes, AST, ALT, AFP, HBV and HCV
	Wen 1'''-2012	D+V	-	MJ cohort	1994	-	2008	8.5 years	general people	Taiwan	10-HCC/PLC/liver cancer	age, sex, pack-year of smoking, alcohol drinking, physical activity, diabetes
	Wen 2'''-2012	D+V	-	MJ cohort	1994	-	2008	8.5 years	general people	Taiwan	10-HCC/PLC/liver cancer	age, sex, AST, ALT
	Wen 3'''-2012	D+V	-	MJ cohort	1994	-	2008	8.5 years	general people	Taiwan	10-HCC/PLC/liver cancer	age, sex, pack-year of smoking, alcohol drinking, physical activity, diabetes, AST, and ALT
	Wen 4'''-2012	D+V	-	MJ cohort	1994	-	2008	8.5 years	general people	Taiwan	10-HCC/PLC/liver cancer	age, sex, pack-year of smoking, alcohol drinking, physical activity, diabetes, AST, ALT, AFP, and HBV
	Wen 5'''-2012	D+V	-	MJ cohort	1994	-	2008	8.5 years	general people	Taiwan	10-HCC/PLC/liver cancer	age, sex, pack-year of smoking, alcohol drinking, physical activity, diabetes, AST, ALT, AFP, HBV and HCV
	10.1016/j.ejim.2013.06.010	HCC-4 Risk Score	D	-	the hepatology section of the Internal Medicine Department in Hospital Virgen de laVictoria in Málaga, Spain	1993	2010	-	82 months	HCV infected	Spain	5-10-HCC/PLC/liver cancer
FRONA		V	External	the hepatology section of the Internal Medicine Department in Hospital Virgen de laVictoria in Málaga, Spain	1993	2010	-	82 months	HCV infected	Spain	5-10-HCC/PLC/liver cancer	-
APRI		V	External	the hepatology section of the Internal Medicine Department in Hospital Virgen de laVictoria in Málaga, Spain	1993	2010	-	82 months	HCV infected	Spain	5-10-HCC/PLC/liver cancer	AST, platelet count
FIB-4		V	External	the hepatology section of the Internal Medicine Department in Hospital Virgen de laVictoria in Málaga, Spain	1993	2010	-	82 months	HCV infected	Spain	5-10-HCC/PLC/liver cancer	age, AST, ALT, and PLT
10.1016/j.yjmed.2012.05.017	Lee-2013	D	-	REVEAL-HBV	1991	1992	-	-	HBV infected	Taiwan	<5-SLD/advanced liver disease/cirrhosis/liver death	age, gender, HBVe antigen (HBeAg) serostatus, serum levels of HBV DNA and alanine aminotransferase (ALT)
	Lee-2013	D	-	REVEAL-HBV	1991	1992	-	-	HBV infected	Taiwan	5-SLD/advanced liver disease/cirrhosis/liver death	age, gender, HBVe antigen (HBeAg) serostatus, serum levels of HBV DNA and alanine aminotransferase (ALT)
	Lee-2013	D	-	REVEAL-HBV	1991	1992	-	-	HBV infected	Taiwan	10-SLD/advanced liver disease/cirrhosis/liver death	age, gender, HBVe antigen (HBeAg) serostatus, serum levels of HBV DNA and alanine aminotransferase (ALT)
	Lee-2013	V	Internal	REVEAL-HBV	1991	1992	-	-	HBV infected	Taiwan	<5-SLD/advanced liver disease/cirrhosis/liver death	age, gender, HBVe antigen (HBeAg) serostatus, serum levels of HBV DNA and alanine aminotransferase (ALT)

10.1002/hep.26385	Lee-2013	V	Internal	REVEAL-HBV	1991	1992	-	-	HBV infected	Taiwan	5-5LD/advanced liver disease/cirrhosis/liver death	age, gender, HBVe antigen (HBeAg) serostatus, serum levels of HBV DNA and alanine aminotransferase (ALT)
	Lee-2013	V	Internal	REVEAL-HBV	1991	1992	-	-	HBV infected	Taiwan	10-5LD/advanced liver disease/cirrhosis/liver death	age, gender, HBVe antigen (HBeAg) serostatus, serum levels of HBV DNA and alanine aminotransferase (ALT)
	Lee-2013	D	-	REVEAL-HBV	1991	1992	-	-	HBV infected	Taiwan	<5-HCC/PLC/liver cancer	age, gender, HBVe antigen (HBeAg) serostatus, serum levels of HBV DNA, alanine aminotransferase (ALT) and family history
	Lee-2013	D	-	REVEAL-HBV	1991	1992	-	-	HBV infected	Taiwan	5-HCC/PLC/liver cancer	age, gender, HBVe antigen (HBeAg) serostatus, serum levels of HBV DNA, alanine aminotransferase (ALT) and family history
	Lee-2013	D	-	REVEAL-HBV	1991	1992	-	-	HBV infected	Taiwan	10-HCC/PLC/liver cancer	age, gender, HBVe antigen (HBeAg) serostatus, serum levels of HBV DNA, alanine aminotransferase (ALT) and family history
	Lee-2013	V	Internal	REVEAL-HBV	1991	1992	-	-	HBV infected	Taiwan	<5-HCC/PLC/liver cancer	age, gender, HBVe antigen (HBeAg) serostatus, serum levels of HBV DNA, alanine aminotransferase (ALT) and family history
	Lee-2013	V	Internal	REVEAL-HBV	1991	1992	-	-	HBV infected	Taiwan	5-HCC/PLC/liver cancer	age, gender, HBVe antigen (HBeAg) serostatus, serum levels of HBV DNA, alanine aminotransferase (ALT) and family history
10.1371/journal.pone.0061448	Lin-Model I	D	-	REVEAL-HBV	1991	1992	2008	5.9 year	HBV infected	Taiwan	5-10-HCC/PLC/liver cancer	age, gender, serum ALT levels, and HBV seromarkers
	Lin-Model II	D	-	REVEAL-HBV	1991	1992	2008	5.9 year	HBV infected	Taiwan	5-10-HCC/PLC/liver cancer	age, gender, and the liver-related seromarkers ALT, AAR, AFP, GGT, albumin, and alpha-1 globulin
	Lin-Model III	D	-	REVEAL-HBV	1991	1992	2008	5.9 year	HBV infected	Taiwan	5-10-HCC/PLC/liver cancer	age, gender, and the liver-related seromarkers ALT, AAR, AFP, GGT, albumin, alpha-1 globulin and HBV seromarkers
10.1371/journal.pone.0094760	Lee-2014	D	-	R.E.V.E.A.L.-HCV Cohort	1991	1992	2008	-	HCV infected	Taiwan	5-HCC/PLC/liver cancer	age, alanine aminotransferase (ALT), the ratio of aspartate aminotransferase to ALT, serum HCV RNA levels and cirrhosis status and HCV genotype
	Lee-2014	D	-	R.E.V.E.A.L.-HCV Cohort	1991	1992	2008	-	HCV infected	Taiwan	10-HCC/PLC/liver cancer	age, alanine aminotransferase (ALT), the ratio of aspartate aminotransferase to ALT, serum HCV RNA levels and cirrhosis status and HCV genotype
	Lee-2014	D	-	R.E.V.E.A.L.-HCV Cohort	1991	1992	2008	-	HCV infected	Taiwan	>10-HCC/PLC/liver cancer	age, alanine aminotransferase (ALT), the ratio of aspartate aminotransferase to ALT, serum HCV RNA levels and cirrhosis status and HCV genotype
	Lee-2014	D	-	R.E.V.E.A.L.-HCV Cohort	1991	1992	2008	-	HCV infected	Taiwan	5-HCC/PLC/liver cancer	age, alanine aminotransferase (ALT), the ratio of aspartate aminotransferase to ALT, serum HCV RNA levels and cirrhosis status and HCV genotype
	Lee-2014	D	-	R.E.V.E.A.L.-HCV Cohort	1991	1992	2008	-	HCV infected	Taiwan	10-HCC/PLC/liver cancer	age, alanine aminotransferase (ALT), the ratio of aspartate aminotransferase to ALT, serum HCV RNA levels and cirrhosis status and HCV genotype
	Lee-2014	V	External	High risk validation cohort	2004	2005	2008	-	HCV infected	Taiwan	>10-HCC/PLC/liver cancer	age, alanine aminotransferase (ALT), the ratio of aspartate aminotransferase to ALT, serum HCV RNA levels and cirrhosis status and HCV genotype
	Lee-2014	V	External	High risk validation cohort	2004	2005	2008	-	HCV infected	Taiwan	5-HCC/PLC/liver cancer	age, alanine aminotransferase (ALT), the ratio of aspartate aminotransferase to ALT, serum HCV RNA levels and cirrhosis status and HCV genotype
10.1158/1940-6207.CAPR-15-0434	Duarte-Salles 1-2016	D	-	EPIC cohort	1991	2000	2006	4.8 years	general people	Western European	5-HCC/PLC/liver cancer	OPN, AFP
	Duarte-Salles 2-2016	D	-	EPIC cohort	1991	2000	2006	4.8 years	general people	Western European	5-HCC/PLC/liver cancer	OPN, GGT, ALP, and AST
	Duarte-Salles 3-2016	D	-	EPIC cohort	1991	2000	2006	4.8 years	general people	Western European	5-HCC/PLC/liver cancer	OPN, AFP, GGT, ALP, and AST
	Duarte-Salles 4-2016	D	-	EPIC cohort	1991	2000	2006	4.8 years	general people	Western European	5-HCC/PLC/liver cancer	GGT, ALP, and AST
	Duarte-Salles 1-2016	V	Internal	EPIC cohort	1991	2000	2006	4.8 years	general people	Western European	5-HCC/PLC/liver cancer	OPN, AFP
	Duarte-Salles 2-2016	V	Internal	EPIC cohort	1991	2000	2006	4.8 years	general people	Western European	5-HCC/PLC/liver cancer	OPN, GGT, ALP, and AST
	Duarte-Salles 3-2016	D	-	EPIC cohort	1991	2000	2006	4.8 years	general people	Western European	<5-HCC/PLC/liver cancer	OPN, AFP, GGT, ALP, and AST
	Duarte-Salles 4-2016	D	-	EPIC cohort	1991	2000	2006	4.8 years	general people	Western European	<5-HCC/PLC/liver cancer	OPN, AFP
	Duarte-Salles 1-2016	D	-	EPIC cohort	1991	2000	2006	4.8 years	general people	Western European	<5-HCC/PLC/liver cancer	OPN, GGT, ALP, and AST
	Duarte-Salles 3-2016	D	-	EPIC cohort	1991	2000	2006	4.8 years	general people	Western European	<5-HCC/PLC/liver cancer	OPN, AFP, GGT, ALP, and AST
Duarte-Salles 4-2016	D	-	EPIC cohort	1991	2000	2006	4.8 years	general people	Western European	<5-HCC/PLC/liver cancer	GGT, ALP, and AST	
10.1002/hep.27654	FIB-4	V	External	Seoul National University Hospital	2003	2010	2010	5.4 years	HBV infected	Korea	5-HCC/PLC/liver cancer	age, AST, ALT, and PLT
	US-FIB-4	V	External	Seoul National University Hospital	2003	2011	2011	5.4 years	HBV infected	Korea	5-HCC/PLC/liver cancer	age, AST, ALT, PLT and US (ultrasound)
10.1136/gutjal-2018-316525	AGED	D	-	a community-based prospective cohort (qidong hepatitis B infection cohort (OBC))	1996				general people	China	5-HCC/PLC/liver cancer	age, gender, ALT, HBVe antigen (HBeAg) and HBV DNA
	AGED	D	-	a community-based prospective cohort (qidong hepatitis B infection cohort (OBC))	1996				general people	China	10-HCC/PLC/liver cancer	age, gender, ALT, HBVe antigen (HBeAg) and HBV DNA
	AGED	D	-	a community-based prospective cohort (qidong hepatitis B infection cohort (OBC))	1996				general people	China	>10-HCC/PLC/liver cancer	age, gender, ALT, HBVe antigen (HBeAg) and HBV DNA
	AGED	D	-	a community-based prospective cohort (qidong hepatitis B infection cohort (OBC))	1996				general people	China	>10-HCC/PLC/liver cancer	age, gender, ALT, HBVe antigen (HBeAg) and HBV DNA
	AGED	V	External	-	2007				HBV infected	China	5-HCC/PLC/liver cancer	age, gender, ALT, HBVe antigen (HBeAg) and HBV DNA
	AGED	V	External	-	2007				HBV infected	China	10-HCC/PLC/liver cancer	age, gender, ALT, HBVe antigen (HBeAg) and HBV DNA

10.1371/journal.pone.0158066	DM-HCC risk score	D	-	Seoul National University Bundang Hospital (SNUBH), a tertiary referral center located at Seongnam, Republic of Korea	2003	-	2014	-	patients with diabetes	Korea	5-HCC/PLC/liver cancer	age, GGT, TG
	DM-HCC risk score	V	Internal	Seoul National University Bundang Hospital (SNUBH), a tertiary referral center located at Seongnam, Republic of Korea	2003	-	2014	-	patients with diabetes	Korea	5-HCC/PLC/liver cancer	age, GGT, TG
10.1093/cid/cis224	MELD	V	External	ERCHIVES	2001	-	-	-	HCV infected	U.S.	<5-SLD/advanced liver disease/cirrhosis/liver death	bilirubin, INR, creatinine
	FIB-4	V	External	ERCHIVES	2001	-	-	-	HCV infected	U.S.	<5-SLD/advanced liver disease/cirrhosis/liver death	age, AST, ALT, and PLT
	Child-Pugh;	V	External	ERCHIVES	2001	-	-	-	HCV infected	U.S.	<5-HCC/PLC/liver cancer	total bilirubin, serum albumin, international malized ratio (INR), and presence and severity of ascites and hepatic encephalopathy
	MELD	V	External	ERCHIVES	2001	-	-	-	HCV infected	U.S.	<5-HCC/PLC/liver cancer	bilirubin, INR, creatinine
	FIB-4	V	External	ERCHIVES	2001	-	-	-	HCV infected	U.S.	<5-HCC/PLC/liver cancer	age, AST, ALT, and PLT
	MELD	V	External	ERCHIVES	2001	-	-	-	HCV infected	U.S.	<5-SLD/advanced liver disease/cirrhosis/liver death	bilirubin, INR, creatinine
	FIB-4	V	External	ERCHIVES	2001	-	-	-	HCV infected	U.S.	<5-SLD/advanced liver disease/cirrhosis/liver death	age, AST, ALT, and PLT
	Child-Pugh;	V	External	ERCHIVES	2001	-	-	-	HCV infected	U.S.	<5-HCC/PLC/liver cancer	total bilirubin, serum albumin, international malized ratio (INR), and presence and severity of ascites and hepatic encephalopathy
	MELD	V	External	ERCHIVES	2001	-	-	-	HCV infected	U.S.	<5-HCC/PLC/liver cancer	bilirubin, INR, creatinine
	FIB-4	V	External	ERCHIVES	2001	-	-	-	HCV infected	U.S.	<5-HCC/PLC/liver cancer	age, AST, ALT, and PLT
	MELD	V	External	ERCHIVES	2001	-	-	-	HCV infected	U.S.	5-SLD/advanced liver disease/cirrhosis/liver death	bilirubin, INR, creatinine
	FIB-4	V	External	ERCHIVES	2001	-	-	-	HCV infected	U.S.	5-SLD/advanced liver disease/cirrhosis/liver death	age, AST, ALT, and PLT
Child-Pugh;	V	External	ERCHIVES	2001	-	-	-	HCV infected	U.S.	5-HCC/PLC/liver cancer	total bilirubin, serum albumin, international malized ratio (INR), and presence and severity of ascites and hepatic encephalopathy	
MELD	V	External	ERCHIVES	2001	-	-	-	HCV infected	U.S.	5-HCC/PLC/liver cancer	bilirubin, INR, creatinine	
FIB-4	V	External	ERCHIVES	2001	-	-	-	HCV infected	U.S.	5-HCC/PLC/liver cancer	age, AST, ALT, and PLT	
10.1002/mc.22505	Methylation Profile Score	D	-	GECC, CGMH	1988	1992	-	-	HBV infected	Taiwan	>10-HCC/PLC/liver cancer	three probes cg00300879, cg06872964, and cg07080864 related methylated sites (in the CNKSR1, IFI44L, and PENK gene)
	Methylation Profile Score	D	-	GECC, CGMH	1988	1992	-	-	HBV infected	Taiwan	>10-HCC/PLC/liver cancer	three probes cg00300879, cg06872964, and cg07080864 related methylated sites (in the CNKSR1, IFI44L, and PENK gene)
	Methylation Profile Score	D	-	multicenter study	1998	2009	-	-	HBV infected	Taiwan	>10-HCC/PLC/liver cancer	three probes cg00300879, cg06872964, and cg07080864 related methylated sites (in the CNKSR1, IFI44L, and PENK gene)
10.1371/journal.pone.0187344	Konerman-2017	V	External	UMHS cohort	1998	2014	2014	-	HCV infected	U.S.	<5-SLD/advanced liver disease/cirrhosis/liver death	APRI, Mean Baseline Platelets, Mean Platelets, Max Platelets, Mean Albumin, Max APRI, Mean Alk Phos, Mean MELD, Diff Mean Albumin, Mean INR, Diff Mean Bilirubin, Mean AFP, Diff Mean INR, Max MELD Baseline APRI Diff Mean MELD, Max AFP, Diff Mean AFP, Baseline AFP, Max Albumin
	Konerman-2017	V	External	UMHS cohort	1998	2014	2014	-	HCV infected	U.S.	<5-SLD/advanced liver disease/cirrhosis/liver death	APRI, Mean Baseline Platelets, Mean Platelets, Max Platelets, Mean Albumin, Max APRI, Mean Alk Phos, Mean MELD, Diff Mean Albumin, Mean INR, Diff Mean Bilirubin, Mean AFP, Diff Mean INR, Max MELD Baseline APRI Diff Mean MELD, Max AFP, Diff Mean AFP, Baseline AFP, Max Albumin
	Konerman-2017	V	External	UMHS cohort	1998	2014	2014	-	HCV infected	U.S.	<5-HCC/PLC/liver cancer	APRI, Mean Baseline Platelets, Mean Platelets, Max Platelets, Mean Albumin, Max APRI, Mean Alk Phos, Mean MELD, Diff Mean Albumin, Mean INR, Diff Mean Bilirubin, Mean AFP, Diff Mean INR, Max MELD Baseline APRI Diff Mean MELD, Max AFP, Diff Mean AFP, Baseline AFP, Max Albumin
	Konerman-2017	V	External	UMHS cohort	1998	2014	2014	-	HCV infected	U.S.	<5-HCC/PLC/liver cancer	APRI, Mean Baseline Platelets, Mean Platelets, Max Platelets, Mean Albumin, Max APRI, Mean Alk Phos, Mean MELD, Diff Mean Albumin, Mean INR, Diff Mean Bilirubin, Mean AFP, Diff Mean INR, Max MELD Baseline APRI Diff Mean MELD, Max AFP, Diff Mean AFP, Baseline AFP, Max Albumin
	mREACH-B	V	External	Chronic Hepatitis B patients who underwent transient elastography at tertiary centres	2006	2012	-	-	HBV infected	South Korea	<5-SLD/advanced liver disease/cirrhosis/liver death	age, gender, Alanine aminotransferase, HBeAg, Liver stiffness
	PAGE-B	V	External	Chronic Hepatitis B patients who underwent transient elastography at tertiary centres	2006	2012	-	-	HBV infected	South Korea	<5-SLD/advanced liver disease/cirrhosis/liver death	age, gender, Platelet count

10.18632/oncotarget.22375

LSM-HCC	V	External	Chronic Hepatitis B patients who underwent transient elastography at tertiary centres	2006	2012	-	-	HBV infected	South Korea	<5-SLD/advanced liver disease/cirrhosis/liver death	LS values, age, serum albumin level, and HBV DNA level
mREACH-B	V	External	Chronic Hepatitis B patients who underwent transient elastography at tertiary centres	2006	2012	-	-	HBV infected	South Korea	5-SLD/advanced liver disease/cirrhosis/liver death	age, gender, Alanine aminotransferase, HBeAg, Liver stiffness
PAGE-B	V	External	Chronic Hepatitis B patients who underwent transient elastography at tertiary centres	2006	2012	-	-	HBV infected	South Korea	5-SLD/advanced liver disease/cirrhosis/liver death	age, gender, Platelet count
LSM-HCC	V	External	Chronic Hepatitis B patients who underwent transient elastography at tertiary centres	2006	2012	-	-	HBV infected	South Korea	5-SLD/advanced liver disease/cirrhosis/liver death	LS values, age, serum albumin level, and HBV DNA level
mREACH-B	V	External	Chronic Hepatitis B patients who underwent transient elastography at tertiary centres	2006	2012	-	-	HBV infected	South Korea	5-10-SLD/advanced liver disease/cirrhosis/liver death	age, gender, Alanine aminotransferase, HBeAg, Liver stiffness
PAGE-B	V	External	Chronic Hepatitis B patients who underwent transient elastography at tertiary centres	2006	2012	-	-	HBV infected	South Korea	5-10-SLD/advanced liver disease/cirrhosis/liver death	age, gender, Platelet count
LSM-HCC	V	External	Chronic Hepatitis B patients who underwent transient elastography at tertiary centres	2006	2012	-	-	HBV infected	South Korea	5-10-SLD/advanced liver disease/cirrhosis/liver death	LS values, age, serum albumin level, and HBV DNA level
mREACH-B	V	External	Chronic Hepatitis B patients who underwent transient elastography at tertiary centres	2006	2012	-	-	HBV infected	South Korea	<5-HCC/PLC/liver cancer	age, gender, Alanine aminotransferase, HBeAg, Liver stiffness
PAGE-B	V	External	Chronic Hepatitis B patients who underwent transient elastography at tertiary centres	2006	2012	-	-	HBV infected	South Korea	<5-HCC/PLC/liver cancer	age, gender, Platelet count
LSM-HCC	V	External	Chronic Hepatitis B patients who underwent transient elastography at tertiary centres	2006	2012	-	-	HBV infected	South Korea	<5-HCC/PLC/liver cancer	LS values, age, serum albumin level, and HBV DNA level
mREACH-B	V	External	Chronic Hepatitis B patients who underwent transient elastography at tertiary centres	2006	2012	-	-	HBV infected	South Korea	5-HCC/PLC/liver cancer	age, gender, Alanine aminotransferase, HBeAg, Liver stiffness
PAGE-B	V	External	Chronic Hepatitis B patients who underwent transient elastography at tertiary centres	2006	2012	-	-	HBV infected	South Korea	5-HCC/PLC/liver cancer	age, gender, Platelet count

	LSM-HCC	V	External	Chronic Hepatitis B patients who underwent transient elastography at tertiary centres	2006	2012	-	-	HBV infected	South Korea	5-HCC/PLC/liver cancer	LS values, age, serum albumin level, and HBV DNA level
	mREACH-B	V	External	Chronic Hepatitis B patients who underwent transient elastography at tertiary centres	2006	2012	-	-	HBV infected	South Korea	5-10-HCC/PLC/liver cancer	age, gender, Alanine aminotransferase, HBeAg, Liver stiffness
	PAGE-B	V	External	Chronic Hepatitis B patients who underwent transient elastography at tertiary centres	2006	2012	-	-	HBV infected	South Korea	5-10-HCC/PLC/liver cancer	age, gender, Platelet count
	LSM-HCC	V	External	Chronic Hepatitis B patients who underwent transient elastography at tertiary centres	2006	2012	-	-	HBV infected	South Korea	5-10-HCC/PLC/liver cancer	LS values, age, serum albumin level, and HBV DNA level
10.1016/j.egh.2015.10.033	REACH-B IIa	D	-	(REVEAL)-HBV cohort	1991	1992	2008	-	HBV infected	Taiwan	<5-HCC/PLC/liver cancer	sex, age (in 5-year increments), serum ALT level, a combined variable for HBeAg serostatus, and serum HBV DNA and HBSAg levels
	REACH-B IIb	D	-	(REVEAL)-HBV cohort	1991	1992	2008	-	HBV infected	Taiwan	<5-HCC/PLC/liver cancer	sex, age, serum ALT levels, and combined variables of HBeAg and serum HBSAg levels
	REACH-B	V	External	(ERADICATE-B) study	1985	2000	2010	-	HBV infected	Taiwan	<5-HCC/PLC/liver cancer	Gender, age, ALT, HBeAg status, hepatitis B virus(HBV)DNA load(copies/mL)
	REACH-B IIa	V	External	(ERADICATE-B) study	1985	2000	2010	-	HBV infected	Taiwan	<5-HCC/PLC/liver cancer	sex, age (in 5-year increments), serum ALT level, a combined variable for HBeAg serostatus, and serum HBV DNA and HBSAg levels
	REACH-B IIb	V	External	(ERADICATE-B) study	1985	2000	2010	-	HBV infected	Taiwan	<5-HCC/PLC/liver cancer	sex, age, serum ALT levels, and combined variables of HBeAg and serum HBSAg levels
	REACH-B	V	External	(ERADICATE-B) study	1985	2000	2010	-	HBV infected	Taiwan	5-HCC/PLC/liver cancer	Gender, age, ALT, HBeAg status, hepatitis B virus(HBV)DNA load(copies/mL)
	REACH-B IIa	V	External	(ERADICATE-B) study	1985	2000	2010	-	HBV infected	Taiwan	5-HCC/PLC/liver cancer	sex, age (in 5-year increments), serum ALT level, a combined variable for HBeAg serostatus, and serum HBV DNA and HBSAg levels
	REACH-B IIb	V	External	(ERADICATE-B) study	1985	2000	2010	-	HBV infected	Taiwan	5-HCC/PLC/liver cancer	sex, age, serum ALT levels, and combined variables of HBeAg and serum HBSAg levels
	REACH-B	V	External	(ERADICATE-B) study	1985	2000	2010	-	HBV infected	Taiwan	10-HCC/PLC/liver cancer	Gender, age, ALT, HBeAg status, hepatitis B virus(HBV)DNA load(copies/mL)
	REACH-B IIa	V	External	(ERADICATE-B) study	1985	2000	2010	-	HBV infected	Taiwan	10-HCC/PLC/liver cancer	sex, age (in 5-year increments), serum ALT level, a combined variable for HBeAg serostatus, and serum HBV DNA and HBSAg levels
	REACH-B IIb	V	External	(ERADICATE-B) study	1985	2000	2010	-	HBV infected	Taiwan	10-HCC/PLC/liver cancer	sex, age, serum ALT levels, and combined variables of HBeAg and serum HBSAg levels
	REACH-B	V	External	(CUHK) study	1997	2000	2008	-	HBV infected	Hong Kong	<5-HCC/PLC/liver cancer	Gender, age, ALT, HBeAg status, hepatitis B virus(HBV)DNA load(copies/mL)
	REACH-B IIa	V	External	(CUHK) study	1997	2000	2008	-	HBV infected	Hong Kong	<5-HCC/PLC/liver cancer	sex, age (in 5-year increments), serum ALT level, a combined variable for HBeAg serostatus, and serum HBV DNA and HBSAg levels
	REACH-B IIb	V	External	(CUHK) study	1997	2000	2008	-	HBV infected	Hong Kong	<5-HCC/PLC/liver cancer	sex, age, serum ALT levels, and combined variables of HBeAg and serum HBSAg levels
	REACH-B	V	External	(CUHK) study	1997	2000	2008	-	HBV infected	Hong Kong	5-HCC/PLC/liver cancer	Gender, age, ALT, HBeAg status, hepatitis B virus(HBV)DNA load(copies/mL)
	REACH-B IIa	V	External	(CUHK) study	1997	2000	2008	-	HBV infected	Hong Kong	5-HCC/PLC/liver cancer	sex, age (in 5-year increments), serum ALT level, a combined variable for HBeAg serostatus, and serum HBV DNA and HBSAg levels
	REACH-B IIb	V	External	(CUHK) study	1997	2000	2008	-	HBV infected	Hong Kong	5-HCC/PLC/liver cancer	sex, age, serum ALT levels, and combined variables of HBeAg and serum HBSAg levels
	REACH-B	V	External	(CUHK) study	1997	2000	2008	-	HBV infected	Hong Kong	10-HCC/PLC/liver cancer	Gender, age, ALT, HBeAg status, hepatitis B virus(HBV)DNA load(copies/mL)
	REACH-B IIa	V	External	(CUHK) study	1997	2000	2008	-	HBV infected	Hong Kong	10-HCC/PLC/liver cancer	sex, age (in 5-year increments), serum ALT level, a combined variable for HBeAg serostatus, and serum HBV DNA and HBSAg levels
	REACH-B IIb	V	External	(CUHK) study	1997	2000	2008	-	HBV infected	Hong Kong	10-HCC/PLC/liver cancer	sex, age, serum ALT levels, and combined variables of HBeAg and serum HBSAg levels
REACH-B	V	External	(CUHK) study	1997	2000	2008	-	HBV infected	Hong Kong	5-HCC/PLC/liver cancer	Gender, age, ALT, HBeAg status, hepatitis B virus(HBV)DNA load(copies/mL)	
REACH-B IIa	V	External	(CUHK) study	1997	2000	2008	-	HBV infected	Hong Kong	5-HCC/PLC/liver cancer	sex, age (in 5-year increments), serum ALT level, a combined variable for HBeAg serostatus, and serum HBV DNA and HBSAg levels	
REACH-B IIb	V	External	(CUHK) study	1997	2000	2008	-	HBV infected	Hong Kong	5-HCC/PLC/liver cancer	sex, age, serum ALT levels, and combined variables of HBeAg and serum HBSAg levels	
REACH-B	V	External	(CUHK) study	1997	2000	2008	-	HBV infected	Hong Kong	10-HCC/PLC/liver cancer	Gender, age, ALT, HBeAg status, hepatitis B virus(HBV)DNA load(copies/mL)	
REACH-B IIa	V	External	(CUHK) study	1997	2000	2008	-	HBV infected	Hong Kong	10-HCC/PLC/liver cancer	sex, age (in 5-year increments), serum ALT level, a combined variable for HBeAg serostatus, and serum HBV DNA and HBSAg levels	
REACH-B IIb	V	External	(CUHK) study	1997	2000	2008	-	HBV infected	Hong Kong	10-HCC/PLC/liver cancer	sex, age, serum ALT levels, and combined variables of HBeAg and serum HBSAg levels	
Li-2018	D	-	-	Patients with type 2 diabetes	2001	2004	2011	8.33 years	patients with diabetes	Taiwan	<5-HCC/PLC/liver cancer	Age, gender, smoking, SGPT (u/l) Hbs1C, comorbidity (liver cirrhosis, hepatitis B, hepatitis C), antidiabetes medication, antihyperlipidemia medication (total/high density lipoprotein cholesterol ratio)
Li-2018	D	-	-	Patients with type 2 diabetes	2001	2004	2011	8.33 years	patients with diabetes	Taiwan	5-HCC/PLC/liver cancer	Age, gender, smoking, SGPT (u/l) Hbs1C, ALT, comorbidity (liver cirrhosis, hepatitis B, hepatitis C), antidiabetes medication, antihyperlipidemia medication (total/high density lipoprotein cholesterol ratio)

10.1053/j.seminocol.2018.07.006	Li-2018	D	-	Patients with type 2 diabetes	2001	2004	2011	8.33 years	patients with diabetes	Taiwan	10-HCC/PLC/liver cancer	Age, gender, smoking, SGPT (u/l) Hba1C, ALT, comorbidity (liver cirrhosis, hepatitis B, hepatitis C), antidiabetes medication, antihyperlipidemia medication (total/high density lipoprotein cholesterol ratio)
	Li-2018	V	Internal	Patients with type 2 diabetes	2001	2004	2011	8.33 years	patients with diabetes	Taiwan	<5-HCC/PLC/liver cancer	Age, gender, smoking, SGPT (u/l) Hba1C, ALT, comorbidity (liver cirrhosis, hepatitis B, hepatitis C), antidiabetes medication, antihyperlipidemia medication (total/high density lipoprotein cholesterol ratio)
	Li-2018	V	Internal	Patients with type 2 diabetes	2001	2004	2011	8.33 years	patients with diabetes	Taiwan	5-HCC/PLC/liver cancer	Age, gender, smoking, SGPT (u/l) Hba1C, ALT, comorbidity (liver cirrhosis, hepatitis B, hepatitis C), antidiabetes medication, antihyperlipidemia medication (total/high density lipoprotein cholesterol ratio)
	Li-2018	V	Internal	Patients with type 2 diabetes	2001	2004	2011	8.33 years	patients with diabetes	Taiwan	10-HCC/PLC/liver cancer	Age, gender, smoking, SGPT (u/l) Hba1C, ALT, comorbidity (liver cirrhosis, hepatitis B, hepatitis C), antidiabetes medication, antihyperlipidemia medication (total/high density lipoprotein cholesterol ratio)
10.3350/cmh.2020.0333	Liang score	D	-	Consesutive adult Chronic Hep B pt (CDARS data from Hospital Authority (Hong Kong))	2000	2018	-	52 months	HBV infected	Hong Kong	5-HCC/PLC/liver cancer	age, gender, HBV DNA, FIB-4
	Liang score	V	External	Treatment naive Korean Chronic Hep B cohort	2000	2017	-	50 months	HBV infected	South Korea	5-HCC/PLC/liver cancer	age, gender, HBV DNA, FIB-4
	GAG-HCC	V	External	Treatment naive Korean Chronic Hep B cohort	2000	2017	-	50 months	HBV infected	South Korea	5-HCC/PLC/liver cancer	Age, gender, core promoter mutaiton, level of HBV DNA, cirrhosis
	REACH-B	V	External	Treatment naive Korean Chronic Hep B cohort	2000	2017	-	50 months	HBV infected	South Korea	5-HCC/PLC/liver cancer	Age, gender, ALT, HBeAg, HBV DNA
	CU-HCC	V	External	Treatment naive Korean Chronic Hep B cohort	2000	2017	-	50 months	HBV infected	South Korea	5-HCC/PLC/liver cancer	-
10.1093/ije/dyaa089	Sinn-2020	D	-	National Health Insurance Service (NHIS)-National Sample Cohort (NSC) (representative sample of 2.2% of Korean citizens enroled in NHIS) - all men and women 20 years of age participating in the NHIS-NSC cohort with at least one health screening between 1 January 2003 and 31 December 2013	2003	2013	-	-	general people	South Korea	10-HCC/PLC/liver cancer	Age, gender, smoking, diabetes, ALT, total cholesterol
	Sinn-2020	V	External	Samsung Medical Center Health Promotion Center Cohort (SMC-HPCC) - men and women 20 years of age who underwent comprehensive health check-up examinations between January 2003 and December 2013, and additional follow-up between January 2003 and November 2017 at Samsung Medical Center,	2003	2013	2017	-	general people	South Korea	10-HCC/PLC/liver cancer	Age, gender, smoking, diabetes, ALT, total cholesterol

10.1111/jvh.13185	Sinn-2019	D	-	Across four academic institutions in South Korea: patients who met all of the following inclusion criteria: (a) adults aged 18 years or older, (b) patients with chronic hepatitis B, defined by presence of hepatitis B surface antigen (HBsAg) for more than 6 months or compatible history, (c) HBV treatment-naïve, (d) no co-infection with hepatitis C virus or human immunodeficiency virus and (e) no history of malignancy including HCC at baseline	2006	2011	-	-	HBV infected	South Korea	5-HCC/PLC/liver cancer	Age, gender, HBeAg, ALT level, platelet count, cirrhosis
10.1002/hep4.1700	dAAR score	D	-	FINRISK	2002	2012	-	-	general people	Finland	5-10-SLD/advanced liver disease/cirrhosis/liver death	age, AAR(aspartate-to-alanine aminotransferase ratio), and ALT
	dAAR score	V	External	Swedish Apolipoprotein Mortality Risk [AMORIS] subcohort	1985	1996	-	-	general people	Sweden	5-SLD/advanced liver disease/cirrhosis/liver death	age, AAR, and ALT
	dAAR score	V	External	Swedish Apolipoprotein Mortality Risk [AMORIS] subcohort	1985	1996	-	-	general people	Sweden	10-SLD/advanced liver disease/cirrhosis/liver death	age, AAR, and ALT
	dAAR score	V	External	Swedish Apolipoprotein Mortality Risk [AMORIS] subcohort	1985	1996	-	-	general people	Sweden	>10-SLD/advanced liver disease/cirrhosis/liver death	age, AAR, and ALT
	FIB-4	V	External	Swedish Apolipoprotein Mortality Risk [AMORIS] subcohort	1985	1996	-	-	general people	Sweden	10-SLD/advanced liver disease/cirrhosis/liver death	age, AST, ALT, and PLT
	APRI	V	External	Swedish Apolipoprotein Mortality Risk [AMORIS] subcohort	1985	1996	-	-	general people	Sweden	10-SLD/advanced liver disease/cirrhosis/liver death	AST, platelet count
	NAFLD Fibrosis Score	V	External	Swedish Apolipoprotein Mortality Risk [AMORIS] subcohort	1985	1996	-	-	general people	Sweden	10-SLD/advanced liver disease/cirrhosis/liver death	age (years) ; BMI (kg/m2) ; diabetes ; AST/ALT ; platelet count ,albumin (g/dL)
	dAAR score	V	External	Swedish Apolipoprotein Mortality Risk [AMORIS] subcohort	1985	2009	-	-	patients with NAFLD	Sweden	5-SLD/advanced liver disease/cirrhosis/liver death	age, AAR, and ALT
	dAAR score	V	External	Swedish Apolipoprotein Mortality Risk [AMORIS] subcohort	1985	2009	-	-	patients with NAFLD	Sweden	10-SLD/advanced liver disease/cirrhosis/liver death	age, AAR, and ALT
	dAAR score	V	External	Swedish Apolipoprotein Mortality Risk [AMORIS] subcohort	1985	2009	-	-	patients with NAFLD	Sweden	>10-SLD/advanced liver disease/cirrhosis/liver death	age, AAR, and ALT
	FIB-4	V	External	Swedish Apolipoprotein Mortality Risk [AMORIS] subcohort	1985	2009	-	-	patients with NAFLD	Sweden	10-SLD/advanced liver disease/cirrhosis/liver death	age, AST, ALT, and PLT
	APRI	V	External	Swedish Apolipoprotein Mortality Risk [AMORIS] subcohort	1985	2009	-	-	patients with NAFLD	Sweden	10-SLD/advanced liver disease/cirrhosis/liver death	AST, platelet count
NAFLD Fibrosis Score	V	External	Swedish Apolipoprotein Mortality Risk [AMORIS] subcohort	1985	2009	-	-	patients with NAFLD	Sweden	10-SLD/advanced liver disease/cirrhosis/liver death	age (years) ; BMI (kg/m2) ; diabetes ; AST/ALT ; platelet count ,albumin (g/dL)	

	dAAR score	V	External	patients with biopsy-proven NAFLD at Karolinska University Hospital, Huddinge, and Linköping University Hospital	1985	2009	-	-	patients with NAFLD	Sweden	>10-SLD/advanced liver disease/cirrhosis/liver death	age, AAR, and ALT
10.21147/J.ISSN.1000-9604.2021.03.07	MALE-ABCD	D	-	CCOP-LC Cohort	2017	-	2019	2 years	HBV infected	China	<5-HCC/PLC/liver cancer	Age, AFP, DCP, GGT, PLT and WBC
	MALE-ABCD	V	Internal	CCOP-LC Cohort	2017	-	2019	2 years	HBV infected	China	<5-HCC/PLC/liver cancer	Age, AFP, DCP, GGT, PLT and WBC
	AGED	V	External	CCOP-LC Cohort	2017	-	2019	2 years	HBV infected	China	<5-HCC/PLC/liver cancer	sex, age, HBeAg, HBV DNA(log copies/mL)
	REACH-B	V	External	CCOP-LC Cohort	2017	-	2019	2 years	HBV infected	China	<5-HCC/PLC/liver cancer	sex, age, ALT, HBeAg status and HBV DNA
	PAGE-B	V	External	CCOP-LC Cohort	2017	-	2019	2 years	HBV infected	China	<5-HCC/PLC/liver cancer	age, sex and platelets
	mPAGE-B	V	External	CCOP-LC Cohort	2017	-	2019	2 years	HBV infected	China	<5-HCC/PLC/liver cancer	platelet, age, sex, albumin
	THRI	V	External	CCOP-LC Cohort	2017	-	2019	2 years	HBV infected	China	<5-HCC/PLC/liver cancer	Age, Etiology, Gender, Platelets
	GALAD	V	External	CCOP-LC Cohort	2017	-	2019	2 years	HBV infected	China	<5-HCC/PLC/liver cancer	age, sex, AFP, AFP-L3 (an isoform of AFP characterized by the presence of an a 1-6-linked residue on the AFP carbohydrate side chain), DCP
10.1136/gutjnl-2016-312993	RWS-HCC	V	External	non-Asian: Gastroenterology and Hepatology, University Hospital of Cologne, Germany	1994	2015	-	-	HBV infected	Germany	10-HCC/PLC/liver cancer	age, gender, cirrhosis, serum AFP
10.1111/jvh.13631	CAP-B Score	D	-	Adult patients with CHB diagnosis from the NHIS database	2005	2015	2017	-	HBV infected	South Korea	<5-SLD/advanced liver disease/cirrhosis/liver death	Sex, age, medical aid, income, chronic hepatitis C, diabetes mellitus, statin exposure, antiplatelet exposure, smoking, ALT, GGT*alcohol consumption
	CAP-B Score	D	-	Adult patients with CHB diagnosis from the NHIS database	2005	2015	2017	-	HBV infected	South Korea	5-SLD/advanced liver disease/cirrhosis/liver death	Sex, age, medical aid, income, chronic hepatitis C, diabetes mellitus, statin exposure, antiplatelet exposure, smoking, ALT, GGT*alcohol consumption
	CAP-B Score	D	-	Adult patients with CHB diagnosis from the NHIS database	2005	2015	2017	-	HBV infected	South Korea	10-SLD/advanced liver disease/cirrhosis/liver death	Sex, age, medical aid, income, chronic hepatitis C, diabetes mellitus, statin exposure, antiplatelet exposure, smoking, ALT, GGT*alcohol consumption
	CAP-B Score	V	Internal	Adult patients with CHB diagnosis from the NHIS database	2005	2015	2017	-	HBV infected	South Korea	<5-SLD/advanced liver disease/cirrhosis/liver death	Sex, age, medical aid, low income, intermediate income, chronic hepatitis C, diabetes mellitus, statin exposure, antiplatelet exposure, smoking, ALT, GGT*alcohol consumption
	CAP-B Score	V	Internal	Adult patients with CHB diagnosis from the NHIS database	2005	2015	2017	-	HBV infected	South Korea	5-SLD/advanced liver disease/cirrhosis/liver death	Sex, age, medical aid, low income, intermediate income, chronic hepatitis C, diabetes mellitus, statin exposure, antiplatelet exposure, smoking, ALT, GGT*alcohol consumption
	CAP-B Score	V	Internal	Adult patients with CHB diagnosis from the NHIS database	2005	2015	2017	-	HBV infected	South Korea	10-SLD/advanced liver disease/cirrhosis/liver death	Sex, age, medical aid, low income, intermediate income, chronic hepatitis C, diabetes mellitus, statin exposure, antiplatelet exposure, smoking, ALT, GGT*alcohol consumption
10.1053/j.gastro.2019.09.008	APRI	V	External	AMORIS	1985	1996	-	-	general people	Sweden	5-SLD/advanced liver disease/cirrhosis/liver death	AST, platelet count
	APRI	V	External	AMORIS	1985	1996	-	-	general people	Sweden	10-SLD/advanced liver disease/cirrhosis/liver death	AST, platelet count
	APRI	V	External	AMORIS	1985	1996	-	-	general people	Sweden	>10-SLD/advanced liver disease/cirrhosis/liver death	AST, platelet count
	BARD	V	External	AMORIS	1985	1996	-	-	general people	Sweden	5-SLD/advanced liver disease/cirrhosis/liver death	BMI, AST, ALT, diabetes
	BARD	V	External	AMORIS	1985	1996	-	-	general people	Sweden	10-SLD/advanced liver disease/cirrhosis/liver death	BMI, AST, ALT, diabetes
	BARD	V	External	AMORIS	1985	1996	-	-	general people	Sweden	>10-SLD/advanced liver disease/cirrhosis/liver death	BMI, AST, ALT, diabetes
	FIB-4	V	External	AMORIS	1985	1996	-	-	general people	Sweden	5-SLD/advanced liver disease/cirrhosis/liver death	Age, AST, platelets, ALT
	FIB-4	V	External	AMORIS	1985	1996	-	-	general people	Sweden	10-SLD/advanced liver disease/cirrhosis/liver death	Age, AST, platelets, ALT
	FIB-4	V	External	AMORIS	1985	1996	-	-	general people	Sweden	>10-SLD/advanced liver disease/cirrhosis/liver death	Age, AST, platelets, ALT
	Forns Score	V	External	AMORIS	1985	1996	-	-	general people	Sweden	5-SLD/advanced liver disease/cirrhosis/liver death	Platelet count, GT, age, cholesterol
	Forns Score	V	External	AMORIS	1985	1996	-	-	general people	Sweden	10-SLD/advanced liver disease/cirrhosis/liver death	Platelet count, GT, age, cholesterol
	Forns Score	V	External	AMORIS	1985	1996	-	-	general people	Sweden	>10-SLD/advanced liver disease/cirrhosis/liver death	Platelet count, GT, age, cholesterol
	NAFLD Fibrosis Score	V	External	AMORIS	1985	1996	-	-	general people	Sweden	5-SLD/advanced liver disease/cirrhosis/liver death	age, BMI, diabetes, AST, ALT, platelet count, albumin
	NAFLD Fibrosis Score	V	External	AMORIS	1985	1996	-	-	general people	Sweden	10-SLD/advanced liver disease/cirrhosis/liver death	age, BMI, diabetes, AST, ALT, platelet count, albumin
	NAFLD Fibrosis Score	V	External	AMORIS	1985	1996	-	-	general people	Sweden	>10-SLD/advanced liver disease/cirrhosis/liver death	age, BMI, diabetes, AST, ALT, platelet count, albumin
	APRI	V	External	AMORIS	1985	1996	-	-	general people	Sweden	10-SLD/advanced liver disease/cirrhosis/liver death	AST, platelet count
	BARD	V	External	AMORIS	1985	1996	-	-	general people	Sweden	10-SLD/advanced liver disease/cirrhosis/liver death	BMI, AST, ALT, diabetes
	FIB-4	V	External	AMORIS	1985	1996	-	-	general people	Sweden	10-SLD/advanced liver disease/cirrhosis/liver death	Age, AST, platelets, ALT
	Forns Score	V	External	AMORIS	1985	1996	-	-	general people	Sweden	10-SLD/advanced liver disease/cirrhosis/liver death	Platelet count, GT, age, cholesterol
	NAFLD Fibrosis Score	V	External	AMORIS	1985	1996	-	-	general people	Sweden	10-SLD/advanced liver disease/cirrhosis/liver death	age, BMI, diabetes, AST, ALT, platelet count, albumin
	D'AS	D	-	patients who received care at Samsung Medical Center, Seoul, Korea	2006	2011	2014	-	HBV infected	South Korea	<5-HCC/PLC/liver cancer	Sex, age, ALT, HBeAg and HBV DNA levels
	D'AS	D	-	patients who received care at Samsung Medical Center, Seoul, Korea	2006	2011	2014	-	HBV infected	South Korea	<5-HCC/PLC/liver cancer	Sex, age, ALT, HBeAg and HBV DNA levels
	D'AS	D	-	patients who received care at Samsung Medical Center, Seoul, Korea	2006	2011	2014	-	HBV infected	South Korea	<5-HCC/PLC/liver cancer	Sex, age, ALT, HBeAg and HBV DNA levels

10.5009/gn16403	D'AS	D	-	patients who received care at Samsung Medical Center, Seoul, Korea	2006	2011	2014	-	HBV infected	South Korea	5-HCC/PLC/liver cancer	Sex, age, ALT, HBeAg and HBV DNA levels
	D'AS	D	-	patients who received care at Samsung Medical Center, Seoul, Korea	2006	2011	2014	-	HBV infected	South Korea	5~10-HCC/PLC/liver cancer	Sex, age, ALT, HBeAg and HBV DNA levels
	D'AS	V	External	f patients who received care at Seoul National University Hospital	2006	2011	2014	-	HBV infected	South Korea	<5-HCC/PLC/liver cancer	Sex, age, ALT, HBeAg and HBV DNA levels
	D'AS	V	External	f patients who received care at Seoul National University Hospital	2006	2011	2014	-	HBV infected	South Korea	<5-HCC/PLC/liver cancer	Sex, age, ALT, HBeAg and HBV DNA levels
	D'AS	V	External	f patients who received care at Seoul National University Hospital	2006	2011	2014	-	HBV infected	South Korea	<5-HCC/PLC/liver cancer	Sex, age, ALT, HBeAg and HBV DNA levels
	D'AS	V	External	f patients who received care at Seoul National University Hospital	2006	2011	2014	-	HBV infected	South Korea	5-HCC/PLC/liver cancer	Sex, age, ALT, HBeAg and HBV DNA levels
	D'AS	V	External	f patients who received care at Seoul National University Hospital	2006	2011	2014	-	HBV infected	South Korea	5~10-HCC/PLC/liver cancer	Sex, age, ALT, HBeAg and HBV DNA levels
10.1186/s12885-021-08498-w	An-2021	D	-	NHIS-2020-2-146	2004	2007	2015	11.1 years	general people	South Korea	5~10-HCC/PLC/liver cancer	age, sex, obesity, income level, the family history of chronic liver disease, ALT, GGT, total blood cholesterol level, and preexisting chronic liver disease, chronic hepatitis virus infection, HIV infection, DM, dyslipidemia, or schizophrenic/delusional disorders or mental disorders due to psychoactive substance use
	An-2021	V	Internal	NHIS-2020-2-146	2004	2007	2015	9.1 years	general people	South Korea	5~10-HCC/PLC/liver cancer	age, sex, obesity, liver function tests, the family history of chronic liver disease, underlying chronic liver disease, chronic hepatitis virus or human immunodeficiency virus infection, and diabetes mellitus income, total cholesterol, and underlying dyslipidemia or schizophrenic/delusional disorders
10.1002/rjc.33487	CKB-PLR	D	-	China Kadoorie Biobank	2004	2008	2017	-	general people	China	10-HCC/PLC/liver cancer	Age, gender, residential area, level of education, previous cancer diagnosis, family history of cancer, history of cirrhosis or chronic hepatitis, history of gall stone or gall bladder disease, BMI, physical activity, random glucose, alcohol smoking
	CKB-PLR	V	Internal	China Kadoorie Biobank	2004	2008	2017	-	general people	China	10-HCC/PLC/liver cancer	Age, gender, residential area, level of education, previous cancer diagnosis, family history of cancer, history of cirrhosis or chronic hepatitis, history of gall stone or gall bladder disease, BMI, physical activity, random glucose, alcohol smoking
	GAG-HCC	V	External	Screening and Surveillance of Hepatocellular Carcinoma Project at Chulabhorn Hospital, Bangkok, Thailand, during July 2010	2010	2017	-	-	HBV infected	Thailand	5-HCC/PLC/liver cancer	liver cirrhosis, age, sex, hepatitis B virus DNA load
	CU-HCC	V	External	Screening and Surveillance of Hepatocellular Carcinoma Project at Chulabhorn Hospital, Bangkok, Thailand, during July 2010	2010	2017	-	-	HBV infected	Thailand	5-HCC/PLC/liver cancer	serum albumin, bilirubin levels, liver stiffness
	REACH-B	V	External	Screening and Surveillance of Hepatocellular Carcinoma Project at Chulabhorn Hospital, Bangkok, Thailand, during July 2010	2010	2017	-	-	HBV infected	Thailand	5-HCC/PLC/liver cancer	sex, age, ALT, HBeAg status and HBVDNA
	PAGE-B	V	External	Screening and Surveillance of Hepatocellular Carcinoma Project at Chulabhorn Hospital, Bangkok, Thailand, during July 2010	2010	2017	-	-	HBV infected	Thailand	5-HCC/PLC/liver cancer	platelet, age, sex

10.1111/jvh.13517	mPAGE-B	V	External	Screening and Surveillance of Hepatocellular Carcinoma Project at Chulabhorn Hospital, Bangkok, Thailand, during July 2010	2010	2017	-	-	HBV infected	Thailand	5-HCC/PLC/liver cancer	platelet, age, sex, albumin
	CAMD	V	External	Screening and Surveillance of Hepatocellular Carcinoma Project at Chulabhorn Hospital, Bangkok, Thailand, during July 2010	2010	2017	-	-	HBV infected	Thailand	5-HCC/PLC/liver cancer	cirrhosis, age, sex, diabetes
	AASL	V	External	Screening and Surveillance of Hepatocellular Carcinoma Project at Chulabhorn Hospital, Bangkok, Thailand, during July 2010	2010	2017	-	-	HBV infected	Thailand	5-HCC/PLC/liver cancer	age, albumin, sex, cirrhosis
	LSM-HCC	V	External	Screening and Surveillance of Hepatocellular Carcinoma Project at Chulabhorn Hospital, Bangkok, Thailand, during July 2010	2010	2017	-	-	HBV infected	Thailand	5-HCC/PLC/liver cancer	liver stiffness, age, albumin, HBV DNA
	mREACH-B	V	External	Screening and Surveillance of Hepatocellular Carcinoma Project at Chulabhorn Hospital, Bangkok, Thailand, during July 2010	2010	2017	-	-	HBV infected	Thailand	5-HCC/PLC/liver cancer	sex, age, ALT, HBeAg, liver stiffness
10.3390/v14040732	PAGE-B	V	External	Liver Studies Center of the University Hospital of the Federal University of Maranhão	-	-	-	-	HBV infected	Brazil	<5-HCC/PLC/liver cancer	age, sex and platelets
	PAGE-B	V	External	Liver Studies Center of the University Hospital of the Federal University of Maranhão	-	-	-	-	HBV infected	Brazil	<5-HCC/PLC/liver cancer	age, sex and platelets
	PAGE-B	V	External	Liver Studies Center of the University Hospital of the Federal University of Maranhão	-	-	-	-	HBV infected	Brazil	<5-HCC/PLC/liver cancer	age, sex and platelets
	REACH-B	V	External	Liver Studies Center of the University Hospital of the Federal University of Maranhão	-	-	-	-	HBV infected	Brazil	<5-HCC/PLC/liver cancer	sex, age, ALT, HBeAg status and HBVDNA
	REACH-B	V	External	Liver Studies Center of the University Hospital of the Federal University of Maranhão	-	-	-	-	HBV infected	Brazil	<5-HCC/PLC/liver cancer	sex, age, ALT, HBeAg status and HBVDNA
	REACH-B	V	External	Liver Studies Center of the University Hospital of the Federal University of Maranhão	-	-	-	-	HBV infected	Brazil	<5-HCC/PLC/liver cancer	sex, age, ALT, HBeAg status and HBVDNA
	Modified HLI	V	Internal	(EPIC) cohort	1992	2000	2010	-	general people	Denmark, France, Germany, Greece, Italy, Netherlands, Norway, Spain, Sweden, and the United Kingdom	10-HCC/PLC/liver cancer	diet, BMI, physical activity, lifetime alcohol, smoking, diabetes, and hepatitis
	Lifestyle signature	D	-	(EPIC) cohort	1992	2000	2010	-	general people	Denmark, France, Germany, Greece, Italy, Netherlands, Norway, Spain, Sweden, and the United Kingdom	10-HCC/PLC/liver cancer	diet, BMI, physical activity, lifetime alcohol, smoking, diabetes, and hepatitis

10.1093/ajcn/nqy074	Metabolic signature	D	-	(EPIC) cohort	1992	2000	2010	-	general people	Denmark, France, Germany, Greece, Italy, Netherlands, Norway, Spain, Sweden, and the United Kingdom	10-HCC/PLC/liver cancer	Glutamic acid, Hexoses, SM(OH)C14:1, SM(OH)C16:1, SM(OH)C22:2, PCaaC32:1, Liver function score
	LFS	D	-	(EPIC) cohort	1992	2000	2010	-	general people	Denmark, France, Germany, Greece, Italy, Netherlands, Norway, Spain, Sweden, and the United Kingdom	10-HCC/PLC/liver cancer	ALT,AST, GGT, alkaline phosphatase, albumin, total bilirubin
	LFS + lifestyle signature	D	-	(EPIC) cohort	1992	2000	2010	-	general people	Denmark, France, Germany, Greece, Italy, Netherlands, Norway, Spain, Sweden, and the United Kingdom	10-HCC/PLC/liver cancer	diet, BMI, physical activity, lifetime alcohol, smoking, diabetes, and hepatitis
	LFS + metabolic signature	D	-	(EPIC) cohort	1992	2000	2010	-	general people	Denmark, France, Germany, Greece, Italy, Netherlands, Norway, Spain, Sweden, and the United Kingdom	10-HCC/PLC/liver cancer	Glutamic acid, Hexoses, SMC16:1, SM(OH)C14:1, SM(OH)C22:2, LysoPC aC28:1, PC aeC30:2
10.1038/ajg.2017.254	FIB-4	V	External	ÉRADICATE-B	1985	2000	-	-	HBV infected	Taiwan	>10-SLD/advanced liver disease/cirrhosis/liver death	age, AST, platelet counts, ALT
10.1038/s41416-022-01851-1	aMAP score	V	External	HCC surveillance programme at the Ogaki Municipal Hospital	1998	2014	2021	11.8 years	general people	Japan	>10-HCC/PLC/liver cancer	Age, sex, bilirubin, albumin, platelets
10.2147/ott.S51986	Transient elastography-based risk estimation	D	-	-	2005	2007	-	-	HBV infected	Korea	<5-HCC/PLC/liver cancer	age, male gender, and liver stiffness values, hepatitis B virus DNA
	Transient elastography-based risk estimation	V	Internal	-	2005	2007	-	-	HBV infected	Korea	<5-HCC/PLC/liver cancer	age, male gender, and liver stiffness values, hepatitis B virus DNA
10.1371/journal.pone.0208141	CS Cox model (average)	D	-	VHA data	2000	2016	-	7 years	HCV infected	US	<5-SLD/advanced liver disease/cirrhosis/liver death	Variable selection frequency for CS Cox model: see supplementary
	CS Cox model (average)	D	-	VHA data	2000	2016	-	7 years	HCV infected	US	<5-SLD/advanced liver disease/cirrhosis/liver death	Variable selection frequency for CS Cox model: see supplementary
	CS Cox model (average)	D	-	VHA data	2000	2016	-	7 years	HCV infected	US	5-SLD/advanced liver disease/cirrhosis/liver death	Variable selection frequency for CS Cox model: see supplementary
	longitudinal Cox model (average)	D	-	VHA data	2000	2016	-	7 years	HCV infected	US	<5-SLD/advanced liver disease/cirrhosis/liver death	Variable selection frequency for CS Cox model: see supplementary
	longitudinal Cox model (average)	D	-	VHA data	2000	2016	-	7 years	HCV infected	US	<5-SLD/advanced liver disease/cirrhosis/liver death	Variable selection frequency for CS Cox model: see supplementary
	longitudinal Cox model (average)	D	-	VHA data	2000	2016	-	7 years	HCV infected	US	5-SLD/advanced liver disease/cirrhosis/liver death	Variable selection frequency for CS Cox model: see supplementary
	CS boosting model (average)	D	-	VHA data	2000	2016	-	7 years	HCV infected	US	<5-SLD/advanced liver disease/cirrhosis/liver death	Variable selection frequency for CS Cox model: see supplementary
	CS boosting model (average)	D	-	VHA data	2000	2016	-	7 years	HCV infected	US	<5-SLD/advanced liver disease/cirrhosis/liver death	Variable selection frequency for CS Cox model: see supplementary
	CS boosting model (average)	D	-	VHA data	2000	2016	-	7 years	HCV infected	US	5-SLD/advanced liver disease/cirrhosis/liver death	Variable selection frequency for CS Cox model: see supplementary
	longitudinal boosting model (average)	D	-	VHA data	2000	2016	-	7 years	HCV infected	US	<5-SLD/advanced liver disease/cirrhosis/liver death	Variable selection frequency for CS Cox model: see supplementary
	longitudinal boosting model (average)	D	-	VHA data	2000	2016	-	7 years	HCV infected	US	<5-SLD/advanced liver disease/cirrhosis/liver death	Variable selection frequency for CS Cox model: see supplementary
	longitudinal boosting model (average)	D	-	VHA data	2000	2016	-	7 years	HCV infected	US	5-SLD/advanced liver disease/cirrhosis/liver death	Variable selection frequency for CS Cox model: see supplementary
	CS Cox model (closest)	D	-	VHA data	2000	2016	-	7 years	HCV infected	US	<5-SLD/advanced liver disease/cirrhosis/liver death	Variable selection frequency for CS Cox model: see supplementary
	CS boosting model (closest)	D	-	VHA data	2000	2016	-	7 years	HCV infected	US	<5-SLD/advanced liver disease/cirrhosis/liver death	Variable selection frequency for CS Cox model: see supplementary
	longitudinal Cox model (closest)	D	-	VHA data	2000	2016	-	7 years	HCV infected	US	<5-SLD/advanced liver disease/cirrhosis/liver death	Variable selection frequency for CS Cox model: see supplementary
	longitudinal boosting model (closest)	D	-	VHA data	2000	2016	-	7 years	HCV infected	US	<5-SLD/advanced liver disease/cirrhosis/liver death	Variable selection frequency for CS Cox model: see supplementary
	CS Cox model (closest)	D	-	VHA data	2000	2016	-	7 years	HCV infected	US	<5-SLD/advanced liver disease/cirrhosis/liver death	Variable selection frequency for CS Cox model: see supplementary
	CS boosting model (closest)	D	-	VHA data	2000	2016	-	7 years	HCV infected	US	<5-SLD/advanced liver disease/cirrhosis/liver death	Variable selection frequency for CS Cox model: see supplementary
	longitudinal Cox model (closest)	D	-	VHA data	2000	2016	-	7 years	HCV infected	US	<5-SLD/advanced liver disease/cirrhosis/liver death	Variable selection frequency for CS Cox model: see supplementary
	longitudinal boosting model (closest)	D	-	VHA data	2000	2016	-	7 years	HCV infected	US	5-SLD/advanced liver disease/cirrhosis/liver death	Variable selection frequency for CS Cox model: see supplementary
10.1093/infdis/jiaa330	Le-2021	D	-	San Francisco Bay Area Cohort	2000	2016	-	-	HBV infected	US	<5-SLD/advanced liver disease/cirrhosis/liver death	Sex, age, diabetes, antiviral treatment status/duration, hepatitis B e-antigen, ALT, AST
	Le-2021	D	-	San Francisco Bay Area Cohort	2000	2016	-	-	HBV infected	US	5-SLD/advanced liver disease/cirrhosis/liver death	Sex, age, diabetes, antiviral treatment status/duration, hepatitis B e-antigen, ALT, AST
	Le-2021	D	-	San Francisco Bay Area Cohort	2000	2016	-	-	HBV infected	US	10-SLD/advanced liver disease/cirrhosis/liver death	Sex, age, diabetes, antiviral treatment status/duration, hepatitis B e-antigen, ALT, AST
	Le-2021	V	External	Kaohsiung Medical University Hospital in Kaohsiung, Taiwan	-	-	-	-	HBV infected	Taiwan	<5-SLD/advanced liver disease/cirrhosis/liver death	Sex, age, diabetes, antiviral treatment status/duration, hepatitis B e-antigen, ALT, AST

	Le-2021	V	External	Kaohsiung Medical University Hospital in Kaohsiung, Taiwan	-	-	-	-	HBV infected	Taiwan	5-SLD/advanced liver disease/cirrhosis/liver death	Sex, age, diabetes, antiviral treatment status/duration, hepatitis B e-antigen, ALT, AST
	Le-2021	V	External	Kaohsiung Medical University Hospital in Kaohsiung, Taiwan	-	-	-	-	HBV infected	Taiwan	10-SLD/advanced liver disease/cirrhosis/liver death	Sex, age, diabetes, antiviral treatment status/duration, hepatitis B e-antigen, ALT, AST
10.3389/fonc.2021.762662	Cao-2021	D	-	CCOP-LC cohort	2017	-	2020	-	HBV infected	Binhai county,Lingbi county, Mengcheng county, Sheyang county, Shenqiu county, Dancheng county, and Yingdong county	<5-HCC/PLC/liver cancer	Sex, Age ,BMI ,Alcohol consumption (g/week ethanol), Liver diseases in mothers, Psychological trauma
	Cao-2021	D	-	CCOP-LC cohort	2017	-	2020	-	HBV infected	Binhai county,Lingbi county, Mengcheng county, Sheyang county, Shenqiu county, Dancheng county, and Yingdong county	<5-HCC/PLC/liver cancer	Sex, Age ,BMI ,Alcohol consumption (g/week ethanol), Liver diseases in mothers, Psychological trauma
	Cao-2021	D	-	CCOP-LC cohort	2017	-	2020	-	HBV infected	Binhai county,Lingbi county, Mengcheng county, Sheyang county, Shenqiu county, Dancheng county, and Yingdong county	<5-HCC/PLC/liver cancer	Sex, Age ,BMI ,Alcohol consumption (g/week ethanol), Liver diseases in mothers, Psychological trauma
	Cao-2021	V	Internal	CCOP-LC cohort	2017	-	2020	-	HBV infected	Binhai county,Lingbi county, Mengcheng county, Sheyang county, Shenqiu county, Dancheng county, and Yingdong county	<5-HCC/PLC/liver cancer	Sex, Age ,BMI ,Alcohol consumption (g/week ethanol), Liver diseases in mothers, Psychological trauma
10.1016/j.egh.2018.11.030	NAFLD Fibrosis Score	V	External	Karolinska University Hospital (Huddinge) and Linköping University Hospital	1971	2009	2014	19.9 years	patients with NAFLD	Sweden	>10-SLD/advanced liver disease/cirrhosis/liver death	age, BMI, hyperglycemia or diabetes, AST/ALT ratio, platelet, albumin
	FIB-4	V	External	Karolinska University Hospital (Huddinge) and Linköping University Hospital	1971	2009	2014	19.9 years	patients with NAFLD	Sweden	>10-SLD/advanced liver disease/cirrhosis/liver death	Platelets, age, aspartate aminotransferase (AST), ALT
	APRI	V	External	Karolinska University Hospital (Huddinge) and Linköping University Hospital	1971	2009	2014	19.9 years	patients with NAFLD	Sweden	>10-SLD/advanced liver disease/cirrhosis/liver death	AST, platelet count
	BARD	V	External	Karolinska University Hospital (Huddinge) and Linköping University Hospital	1971	2009	2014	19.9 years	patients with NAFLD	Sweden	>10-SLD/advanced liver disease/cirrhosis/liver death	BMI, AST, ALT, diabetes
	LS-Based Model 1	D	-	Severance Hospital, Samsung Medical Center, and Gangnam Severance Hospital	2012	2020	-	60.7 months	patients with NAFLD	Korea	5-HCC/PLC/liver cancer	age, platelet count, and categorized LS,together with AST level (>34 IU/mL)
	LS-Based Model 1	D	-	Severance Hospital, Samsung Medical Center, and Gangnam Severance Hospital	2012	2020	-	60.7 months	patients with NAFLD	Korea	<5-HCC/PLC/liver cancer	age, platelet count, and categorized LS,together with AST level (>34 IU/mL)
	LS-Based Model 1	D	-	Severance Hospital, Samsung Medical Center, and Gangnam Severance Hospital	2012	2020	-	60.7 months	patients with NAFLD	Korea	<5-HCC/PLC/liver cancer	age, platelet count, and categorized LS,together with AST level (>34 IU/mL)
	LS-Based Model 1	D	-	Severance Hospital, Samsung Medical Center, and Gangnam Severance Hospital	2012	2020	-	60.7 months	patients with NAFLD	Korea	5-HCC/PLC/liver cancer	age, platelet count, and categorized LS,together with AST level (>34 IU/mL)
	LS-Based Model 2	D	-	Severance Hospital, Samsung Medical Center, and Gangnam Severance Hospital	2012	2020	-	60.7 months	patients with NAFLD	Korea	5-HCC/PLC/liver cancer	age, platelet count, and categorized LS,together with AST level (>34 IU/mL)
	LS-Based Model 2	D	-	Severance Hospital, Samsung Medical Center, and Gangnam Severance Hospital	2012	2020	-	60.7 months	patients with NAFLD	Korea	<5-HCC/PLC/liver cancer	age, platelet count, and categorized LS,together with AST level (>34 IU/mL)
	LS-Based Model 2	D	-	Severance Hospital, Samsung Medical Center, and Gangnam Severance Hospital	2012	2020	-	60.7 months	patients with NAFLD	Korea	<5-HCC/PLC/liver cancer	age, platelet count, and categorized LS,together with AST level (>34 IU/mL)

	LS-Based Model 2	V	External	Kyungpook National University Hospital	-	-	-	28.2 months	patients with NAFLD	Korea	<5-HCC/PLC/liver cancer	age, platelet count, and categorized LS,together with AST level (>34 IU/mL)
	LS-Based Model 2	V	External	Kyungpook National University Hospital	-	-	-	28.2 months	patients with NAFLD	Korea	5-HCC/PLC/liver cancer	age, platelet count, and categorized LS,together with AST level (>34 IU/mL)
	LS-Based Model 3	V	External	Kyungpook National University Hospital	-	-	-	28.2 months	patients with NAFLD	Korea	5-HCC/PLC/liver cancer	age, platelet count, and categorized LS,together with AST level (>34 IU/mL)
	LS-Based Model 3	V	External	Kyungpook National University Hospital	-	-	-	28.2 months	patients with NAFLD	Korea	<5-HCC/PLC/liver cancer	age, platelet count, and categorized LS,together with AST level (>34 IU/mL)
	LS-Based Model 3	V	External	Kyungpook National University Hospital	-	-	-	28.2 months	patients with NAFLD	Korea	<5-HCC/PLC/liver cancer	age, platelet count, and categorized LS,together with AST level (>34 IU/mL)
	LS-Based Model 3	V	External	Kyungpook National University Hospital	-	-	-	28.2 months	patients with NAFLD	Korea	5-HCC/PLC/liver cancer	age, platelet count, and categorized LS,together with AST level (>34 IU/mL)
10.1111/apt.15082	LCR1	D	-	Groupe Hospitalier Pitié Salpêtrière cohort	1997	2012	-	-	general people	France	10-HCC/PLC/liver cancer	hepatoprotective proteins (apolipoproteinA1, haptoglobin) , gender, age, gamma-glutamyltranspeptidase, marker of fibrosis (alpha2-macroglobulin)
	LCR1	V	Internal	Groupe Hospitalier Pitié Salpêtrière cohort	1997	2012	-	-	general people	France	10-HCC/PLC/liver cancer	hepatoprotective proteins (apolipoproteinA1, haptoglobin) , gender, age, gamma-glutamyltranspeptidase, marker of fibrosis (alpha2-macroglobulin)
	LCR1	D+V	-	Groupe Hospitalier Pitié Salpêtrière cohort	1997	2012	-	-	general people	France	10-HCC/PLC/liver cancer	hepatoprotective proteins (apolipoproteinA1, haptoglobin) , gender, age, gamma-glutamyltranspeptidase, marker of fibrosis (alpha2-macroglobulin)
	LCR2	D	-	Groupe Hospitalier Pitié Salpêtrière cohort	1997	2012	-	-	general people	France	5-HCC/PLC/liver cancer	hepatoprotective proteins (apolipoproteinA1, haptoglobin) , gender, age, gamma-glutamyltranspeptidase, marker of fibrosis (alpha2-macroglobulin)
	LCR2	V	Internal	Groupe Hospitalier Pitié Salpêtrière cohort	1997	2012	-	-	general people	France	5-HCC/PLC/liver cancer	hepatoprotective proteins (apolipoproteinA1, haptoglobin) , gender, age, gamma-glutamyltranspeptidase, marker of fibrosis (alpha2-macroglobulin)
	LCR2	D	-	Groupe Hospitalier Pitié Salpêtrière cohort	1997	2012	-	-	general people	France	5-HCC/PLC/liver cancer	hepatoprotective proteins (apolipoproteinA1, haptoglobin) , gender, age, gamma-glutamyltranspeptidase, marker of fibrosis (alpha2-macroglobulin)
10.2147/JHC.S341045	Elaborate Base Model	D	-	NIH-AARP Diet and Health Study Cohort	1995	1996	2011	16 years	general people	USA	>10-HCC/PLC/liver cancer	age, sex, BMI , height , diabetes, general health status (excellent/very good, good, fair/poor), alcohol, moderate-to-vigorous physical activity (< 3 times/week, ≥3 times/week), dietary cholesterol, saturated fat, trans-fatty acids, ounce equivalents of lean meat from eggs per day, dietary vitamin B6, and healthy eating index scores
	Elaborate Base Model	V	Internal	NIH-AARP Diet and Health Study Cohort	1995	1996	2011	16 years	general people	USA	>10-HCC/PLC/liver cancer	age, sex, BMI , height , diabetes, general health status (excellent/very good, good, fair/poor), alcohol, moderate-to-vigorous physical activity (< 3 times/week, ≥3 times/week), dietary cholesterol, saturated fat, trans-fatty acids, ounce equivalents of lean meat from eggs per day, dietary vitamin B6, and healthy eating index scores
	Parsimonious Base Mode	D	-	NIH-AARP Diet and Health Study Cohort	1995	1996	2011	16 years	general people	USA	>10-HCC/PLC/liver cancer	age, sex, BMI, diabetes, general health status, alcohol, moderate-to-vigorous physical activity, ounce equivalents of lean meat from eggs per day, and healthy eating index scores
	Parsimonious Base Mode	V	Internal	NIH-AARP Diet and Health Study Cohort	1995	1996	2011	16 years	general people	USA	>10-HCC/PLC/liver cancer	age, sex, BMI, diabetes, general health status, alcohol, moderate-to-vigorous physical activity, ounce equivalents of lean meat from eggs per day, and healthy eating index scores
	Elaborate Base Model	V	Internal	NIH-AARP Diet and Health Study Cohort	1995	1996	2011	16 years	general people	USA	>10-HCC/PLC/liver cancer	age, sex, BMI , height , diabetes, general health status (excellent/very good, good, fair/poor), alcohol, moderate-to-vigorous physical activity (< 3 times/week, ≥3 times/week), dietary cholesterol, saturated fat, trans-fatty acids, ounce equivalents of lean meat from eggs per day, dietary vitamin B6, and healthy eating index scores
10.1016/j.jhep.2013.09.029	CU-HCC	V	External	Prince of Wales Hospital	2006	2008	-	69 months	HBV infected	Hong Kong	<5-HCC/PLC/liver cancer	age, albumin, bilirubin, HBV DNA,and clinical cirrhosis;
	LSM-HCC	D	-	Prince of Wales Hospital	2007	2009	-	69 months	HBV infected	Hong Kong	<5-HCC/PLC/liver cancer	age, albumin, Liver stiffness measurement, HBV DNA,
	CU-HCC	V	External	Prince of Wales Hospital	2008	2010	-	69 months	HBV infected	Hong Kong	5-HCC/PLC/liver cancer	age, albumin, bilirubin, HBV DNA,and clinical cirrhosis;
	LSM-HCC	D	-	Prince of Wales Hospital	2009	2011	-	69 months	HBV infected	Hong Kong	5-HCC/PLC/liver cancer	age, albumin, Liver stiffness measurement, HBV DNA,
	CU-HCC	V	External	Prince of Wales Hospital	2010	2012	-	70 months	HBV infected	Hong Kong	<5-HCC/PLC/liver cancer	age, albumin, bilirubin, HBV DNA,and clinical cirrhosis;
	LSM-HCC	V	Internal	Prince of Wales Hospital	2011	2013	-	70 months	HBV infected	Hong Kong	<5-HCC/PLC/liver cancer	age, albumin, Liver stiffness measurement, HBV DNA,
	CU-HCC	V	External	Prince of Wales Hospital	2012	2014	-	70 months	HBV infected	Hong Kong	5-HCC/PLC/liver cancer	age, albumin, bilirubin, HBV DNA,and clinical cirrhosis;
10.1016/j.jhepr.2021.100298	LCR1:LCR2	V	External	ANRS CO22 Hepather cohort	2012	2015	2020	-	HCV infected	France	5-HCC/PLC/liver cancer	-
	LCR1:LCR2	V	External	ANRS CO22 Hepather cohort	2012	2015	2020	-	HCV infected	France	10-HCC/PLC/liver cancer	-
	LCR1:LCR2	V	External	ANRS CO22 Hepather cohort	2012	2015	2020	-	HCV infected	France	5~10-HCC/PLC/liver cancer	-
	ANN-model 1	D	-	NHIRD	2000	2003	2009	-	patients with diabetes	Taiwan	5~10-HCC/PLC/liver cancer	sex, age,alcoholic cirrhosis, nonalcoholic cirrhosis, alcoholic hepatitis, viral hepatitis, other types of chronic hepatitis, alcoholic fatty liver disease, other types of fatty liver disease, and hyperlipidemia
	LR-model 1	D	-	NHIRD	2000	2003	2009	-	patients with diabetes	Taiwan	5~10-HCC/PLC/liver cancer	sex, age,alcoholic cirrhosis, nonalcoholic cirrhosis, alcoholic hepatitis, viral hepatitis, other types of chronic hepatitis, alcoholic fatty liver disease, other types of fatty liver disease, and hyperlipidemia

10.1016/j.cmpb.2015.11.009	ANN-model 2	D	-	NHIRD	2000	2003	2009	-	patients with diabetes	Taiwan	5~10-HCC/PLC/liver cancer	sex, age, alcoholic cirrhosis, alcoholic hepatitis, alcoholic fatty liver disease
	LR-model 2	D	-	NHIRD	2000	2003	2009	-	patients with diabetes	Taiwan	5~10-HCC/PLC/liver cancer	sex, age, alcoholic cirrhosis, alcoholic hepatitis, alcoholic fatty liver disease
	ANN-model 3	D	-	NHIRD	2000	2003	2009	-	patients with diabetes	Taiwan	5~10-HCC/PLC/liver cancer	sex, age, nonalcoholic cirrhosis, viral hepatitis, other types of chronic hepatitis, other types of fatty liver disease, and hyperlipidemia.
	LR-model 3	D	-	NHIRD	2000	2003	2009	-	patients with diabetes	Taiwan	5~10-HCC/PLC/liver cancer	sex, age, nonalcoholic cirrhosis, viral hepatitis, other types of chronic hepatitis, other types of fatty liver disease, and hyperlipidemia.
10.1111/iv.12621	LSPS	D	-	Consecutive patients with CHB who underwent both LB and transient elastography on the same day from January 2006 to February 2010 were identified from the database of Severance Hospital, Yonsei University College of Medicine, Seoul, Korea	2010	2016	-	-	HBV infected	South Korea	5-HCC/PLC/liver cancer	Liver stiffness, spleen diameter, platelet count
	ASPRI	V	External	Consecutive patients with CHB who underwent both LB and transient elastography on the same day from January 2006 to February 2010 were identified from the database of Severance Hospital, Yonsei University College of Medicine, Seoul, Korea	2010	2016	-	-	HBV infected	South Korea	5-HCC/PLC/liver cancer	-
	LS	V	External	Consecutive patients with CHB who underwent both LB and transient elastography on the same day from January 2006 to February 2010 were identified from the database of Severance Hospital, Yonsei University College of Medicine, Seoul, Korea	2010	2016	-	-	HBV infected	South Korea	5-HCC/PLC/liver cancer	Liver stiffness (LS) value using transient elastography
	FIB-4	V	External	Consecutive patients with CHB who underwent both LB and transient elastography on the same day from January 2006 to February 2010 were identified from the database of Severance Hospital, Yonsei University College of Medicine, Seoul, Korea	2010	2016	-	-	HBV infected	South Korea	5-HCC/PLC/liver cancer	Platelets, age, aspartate aminotransferase (AST), ALT
	APRI	V	External	Consecutive patients with CHB who underwent both LB and transient elastography on the same day from January 2006 to February 2010 were identified from the database of Severance Hospital, Yonsei University College of Medicine, Seoul, Korea	2010	2016	-	-	HBV infected	South Korea	5-HCC/PLC/liver cancer	AST, platelet count
10.1111/iv.13489	APRI	V	External	This is a retrospective cohort study of chronic HBV-infected patients who received care at Samsung Medical Center in Seoul, Korea	2006	2011	2016	-	HBV infected	South Korea	5-HCC/PLC/liver cancer	AST, platelet count
	FIB-4	V	External	This is a retrospective cohort study of chronic HBV-infected patients who received care at Samsung Medical Center in Seoul, Korea	2006	2011	2016	-	HBV infected	South Korea	5-HCC/PLC/liver cancer	Platelets, age, aspartate aminotransferase (AST), ALT

	APRI+FIB4	V	External	This is a retrospective cohort study of chronic HBV-infected patients who received care at Samsung Medical Center in Seoul, Korea	2006	2011	2016	-	HBV infected	South Korea	5-HCC/PLC/liver cancer	AST, platelets, age, ALT
10.1002/hep.28115	CU-HCC	V	External	Severance Hospital, Yonsei University College of Medicine (Seoul, Republic of Korea)	2006	2011	-	-	HBV infected	South Korea	<5-HCC/PLC/liver cancer	Age,Albumin, Bilirubin, HBV DNA, Cirrhosis
	GAG-HCC	V	External	Severance Hospital, Yonsei University College of Medicine (Seoul, Republic of Korea)	2006	2011	-	-	HBV infected	South Korea	<5-HCC/PLC/liver cancer	Sex,Age ,HBV DNA , Core promoter mutations, Cirrhosis
	REACH-B	V	External	Severance Hospital, Yonsei University College of Medicine (Seoul, Republic of Korea)	2006	2011	-	-	HBV infected	South Korea	<5-HCC/PLC/liver cancer	Sex ,Age , ALT , HBeAg,HBV DNA
	LSM-HCC	V	External	Severance Hospital, Yonsei University College of Medicine (Seoul, Republic of Korea)	2006	2011	-	-	HBV infected	South Korea	<5-HCC/PLC/liver cancer	Age , Albumin, HBV DNA ,Liver stiffness
	mREACH-B	V	External	Severance Hospital, Yonsei University College of Medicine (Seoul, Republic of Korea)	2006	2011	-	-	HBV infected	South Korea	<5-HCC/PLC/liver cancer	Sex ,Age ,ALT ,HBeAg ,Liver stiffness
	CU-HCC	V	External	Severance Hospital, Yonsei University College of Medicine (Seoul, Republic of Korea)	2006	2011	-	-	HBV infected	South Korea	5-HCC/PLC/liver cancer	Age ,Albumin, Bilirubin, HBV DNA, Cirrhosis
	GAG-HCC	V	External	Severance Hospital, Yonsei University College of Medicine (Seoul, Republic of Korea)	2006	2011	-	-	HBV infected	South Korea	5-HCC/PLC/liver cancer	Sex,Age ,HBV DNA , Core promoter mutations, Cirrhosis
	REACH-B	V	External	Severance Hospital, Yonsei University College of Medicine (Seoul, Republic of Korea)	2006	2011	-	-	HBV infected	South Korea	5-HCC/PLC/liver cancer	Sex ,Age , ALT , HBeAg,HBV DNA
	LSM-HCC	V	External	Severance Hospital, Yonsei University College of Medicine (Seoul, Republic of Korea)	2006	2011	-	-	HBV infected	South Korea	5-HCC/PLC/liver cancer	Age , Albumin, HBV DNA ,Liver stiffness
	mREACH-B	V	External	Severance Hospital, Yonsei University College of Medicine (Seoul, Republic of Korea)	2006	2011	-	-	HBV infected	South Korea	5-HCC/PLC/liver cancer	Sex ,Age ,ALT ,HBeAg ,Liver stiffness
	CU-HCC	V	External	Severance Hospital, Yonsei University College of Medicine (Seoul, Republic of Korea)	2006	2011	-	-	HBV infected	South Korea	<5-SLD/advanced liver disease/cirrhosis/liver death	Age ,Albumin, Bilirubin, HBV DNA, Cirrhosis
	GAG-HCC	V	External	Severance Hospital, Yonsei University College of Medicine (Seoul, Republic of Korea)	2006	2011	-	-	HBV infected	South Korea	<5-SLD/advanced liver disease/cirrhosis/liver death	Sex,Age ,HBV DNA , Core promoter mutations, Cirrhosis
	REACH-B	V	External	Severance Hospital, Yonsei University College of Medicine (Seoul, Republic of Korea)	2006	2011	-	-	HBV infected	South Korea	<5-SLD/advanced liver disease/cirrhosis/liver death	Sex ,Age , ALT , HBeAg,HBV DNA
LSM-HCC	V	External	Severance Hospital, Yonsei University College of Medicine (Seoul, Republic of Korea)	2006	2011	-	-	HBV infected	South Korea	<5-SLD/advanced liver disease/cirrhosis/liver death	Age , Albumin, HBV DNA ,Liver stiffness	

mREACH-B	V	External	Severance Hospital, Yonsei University College of Medicine (Seoul, Republic of Korea)	2006	2011	-	-	HBV infected	South Korea	<5-SLD/advanced liver disease/cirrhosis/liver death	Sex ,Age ,ALT ,HBeAg ,Liver stiffness
CU-HCC	V	External	Severance Hospital, Yonsei University College of Medicine (Seoul, Republic of Korea)	2006	2011	-	-	HBV infected	South Korea	5-SLD/advanced liver disease/cirrhosis/liver death	Age ,Albumin, Bilirubin, HBV DNA, Cirrhosis
GAG-HCC	V	External	Severance Hospital, Yonsei University College of Medicine (Seoul, Republic of Korea)	2006	2011	-	-	HBV infected	South Korea	5-SLD/advanced liver disease/cirrhosis/liver death	Sex, Age ,HBV DNA , Core promoter mutations, Cirrhosis
REACH-B	V	External	Severance Hospital, Yonsei University College of Medicine (Seoul, Republic of Korea)	2006	2011	-	-	HBV infected	South Korea	5-SLD/advanced liver disease/cirrhosis/liver death	Sex ,Age , ALT , HBeAg, HBV DNA
LSM-HCC	V	External	Severance Hospital, Yonsei University College of Medicine (Seoul, Republic of Korea)	2006	2011	-	-	HBV infected	South Korea	5-SLD/advanced liver disease/cirrhosis/liver death	Age , Albumin, HBV DNA ,Liver stiffness
mREACH-B	V	External	Severance Hospital, Yonsei University College of Medicine (Seoul, Republic of Korea)	2006	2011	-	-	HBV infected	South Korea	5-SLD/advanced liver disease/cirrhosis/liver death	Sex ,Age ,ALT ,HBeAg ,Liver stiffness
CU-HCC	V	External	From 2006 to 2014, a total of 1505 CHB patients who underwent LS measurements using TE at different time points at Severance Hospital, Yonsei University College of Medicine, Seoul, Korea	2006	2014	-	-	HBV infected	South Korea	<5-HCC/PLC/liver cancer	Age ,Albumin, Bilirubin, HBV DNA, Cirrhosis
REACH-B	V	External	From 2006 to 2014, a total of 1505 CHB patients who underwent LS measurements using TE at different time points at Severance Hospital, Yonsei University College of Medicine, Seoul, Korea	2006	2014	-	-	HBV infected	South Korea	<5-HCC/PLC/liver cancer	Sex ,Age , ALT , HBeAg, HBV DNA
LSM-HCC	V	External	From 2006 to 2014, a total of 1505 CHB patients who underwent LS measurements using TE at different time points at Severance Hospital, Yonsei University College of Medicine, Seoul, Korea	2006	2014	-	-	HBV infected	South Korea	<5-HCC/PLC/liver cancer	Age , Albumin, HBV DNA ,Liver stiffness
mREACH-B	V	External	From 2006 to 2014, a total of 1505 CHB patients who underwent LS measurements using TE at different time points at Severance Hospital, Yonsei University College of Medicine, Seoul, Korea	2006	2014	-	-	HBV infected	South Korea	<5-HCC/PLC/liver cancer	Sex ,Age ,ALT ,HBeAg ,Liver stiffness
CU-HCC	V	External	From 2006 to 2014, a total of 1505 CHB patients who underwent LS measurements using TE at different time points at Severance Hospital, Yonsei University College of Medicine, Seoul, Korea	2006	2014	-	-	HBV infected	South Korea	5-HCC/PLC/liver cancer	Age ,Albumin, Bilirubin, HBV DNA, Cirrhosis

REACH-B	V	External	From 2006 to 2014, a total of 1505 CHB patients who underwent LS measurements using TE at different time points at Severance Hospital, Yonsei University College of Medicine, Seoul, Korea	2006	2014	-	-	HBV infected	South Korea	5-HCC/PLC/liver cancer	Sex ,Age , ALT , HBeAg,HBV DNA
LSM-HCC	V	External	From 2006 to 2014, a total of 1505 CHB patients who underwent LS measurements using TE at different time points at Severance Hospital, Yonsei University College of Medicine, Seoul, Korea	2006	2014	-	-	HBV infected	South Korea	5-HCC/PLC/liver cancer	Age , Albumin, HBV DNA ,Liver stiffness
mREACH-B	V	External	From 2006 to 2014, a total of 1505 CHB patients who underwent LS measurements using TE at different time points at Severance Hospital, Yonsei University College of Medicine, Seoul, Korea	2006	2014	-	-	HBV infected	South Korea	5-HCC/PLC/liver cancer	Sex ,Age ,ALT ,HBeAg ,Liver stiffness
CU-HCC	V	External	From 2006 to 2014, a total of 1505 CHB patients who underwent LS measurements using TE at different time points at Severance Hospital, Yonsei University College of Medicine, Seoul, Korea	2006	2014	-	-	HBV infected	South Korea	5~10-HCC/PLC/liver cancer	Age ,Albumin, Bilirubin, HBV DNA, Cirrhosis
REACH-B	V	External	From 2006 to 2014, a total of 1505 CHB patients who underwent LS measurements using TE at different time points at Severance Hospital, Yonsei University College of Medicine, Seoul, Korea	2006	2014	-	-	HBV infected	South Korea	5~10-HCC/PLC/liver cancer	Sex ,Age , ALT , HBeAg,HBV DNA
LSM-HCC	V	External	From 2006 to 2014, a total of 1505 CHB patients who underwent LS measurements using TE at different time points at Severance Hospital, Yonsei University College of Medicine, Seoul, Korea	2006	2014	-	-	HBV infected	South Korea	5~10-HCC/PLC/liver cancer	Age , Albumin, HBV DNA ,Liver stiffness
mREACH-B	V	External	From 2006 to 2014, a total of 1505 CHB patients who underwent LS measurements using TE at different time points at Severance Hospital, Yonsei University College of Medicine, Seoul, Korea	2006	2014	-	-	HBV infected	South Korea	5~10-HCC/PLC/liver cancer	Sex ,Age ,ALT ,HBeAg ,Liver stiffness
CU-HCC	V	External	From 2006 to 2014, a total of 1505 CHB patients who underwent LS measurements using TE at different time points at Severance Hospital, Yonsei University College of Medicine, Seoul, Korea	2006	2014	-	-	HBV infected	South Korea	<5-HCC/PLC/liver cancer	Age ,Albumin, Bilirubin, HBV DNA, Cirrhosis

REACH-B	V	External	From 2006 to 2014, a total of 1505 CHB patients who underwent LS measurements using TE at different time points at Severance Hospital, Yonsei University College of Medicine, Seoul, Korea	2006	2014	-	-	HBV infected	South Korea	<5-HCC/PLC/liver cancer	Sex ,Age , ALT , HBeAg,HBV DNA
LSM-HCC	V	External	From 2006 to 2014, a total of 1505 CHB patients who underwent LS measurements using TE at different time points at Severance Hospital, Yonsei University College of Medicine, Seoul, Korea	2006	2014	-	-	HBV infected	South Korea	<5-HCC/PLC/liver cancer	Age , Albumin, HBV DNA ,Liver stiffness
mREACH-B	V	External	From 2006 to 2014, a total of 1505 CHB patients who underwent LS measurements using TE at different time points at Severance Hospital, Yonsei University College of Medicine, Seoul, Korea	2006	2014	-	-	HBV infected	South Korea	<5-HCC/PLC/liver cancer	Sex ,Age ,ALT ,HBeAg ,Liver stiffness
CU-HCC	V	External	From 2006 to 2014, a total of 1505 CHB patients who underwent LS measurements using TE at different time points at Severance Hospital, Yonsei University College of Medicine, Seoul, Korea	2006	2014	-	-	HBV infected	South Korea	5-HCC/PLC/liver cancer	Age ,Albumin, Bilirubin, HBV DNA, Cirrhosis
REACH-B	V	External	From 2006 to 2014, a total of 1505 CHB patients who underwent LS measurements using TE at different time points at Severance Hospital, Yonsei University College of Medicine, Seoul, Korea	2006	2014	-	-	HBV infected	South Korea	5-HCC/PLC/liver cancer	Sex ,Age , ALT , HBeAg,HBV DNA
LSM-HCC	V	External	From 2006 to 2014, a total of 1505 CHB patients who underwent LS measurements using TE at different time points at Severance Hospital, Yonsei University College of Medicine, Seoul, Korea	2006	2014	-	-	HBV infected	South Korea	5-HCC/PLC/liver cancer	Age , Albumin, HBV DNA ,Liver stiffness
mREACH-B	V	External	From 2006 to 2014, a total of 1505 CHB patients who underwent LS measurements using TE at different time points at Severance Hospital, Yonsei University College of Medicine, Seoul, Korea	2006	2014	-	-	HBV infected	South Korea	5-HCC/PLC/liver cancer	Sex ,Age ,ALT ,HBeAg ,Liver stiffness
CU-HCC	V	External	From 2006 to 2014, a total of 1505 CHB patients who underwent LS measurements using TE at different time points at Severance Hospital, Yonsei University College of Medicine, Seoul, Korea	2006	2014	-	-	HBV infected	South Korea	5-10-HCC/PLC/liver cancer	Age ,Albumin, Bilirubin, HBV DNA, Cirrhosis

	REACH-B	V	External	From 2006 to 2014, a total of 1505 CHB patients who underwent LS measurements using TE at different time points at Severance Hospital, Yonsei University College of Medicine, Seoul, Korea	2006	2014	-	-	HBV infected	South Korea	5-10-HCC/PLC/liver cancer	Sex ,Age , ALT , HBeAg,HBV DNA
	LSM-HCC	V	External	From 2006 to 2014, a total of 1505 CHB patients who underwent LS measurements using TE at different time points at Severance Hospital, Yonsei University College of Medicine, Seoul, Korea	2006	2014	-	-	HBV infected	South Korea	5-10-HCC/PLC/liver cancer	Age , Albumin, HBV DNA ,Liver stiffness
	mREACH-B	V	External	From 2006 to 2014, a total of 1505 CHB patients who underwent LS measurements using TE at different time points at Severance Hospital, Yonsei University College of Medicine, Seoul, Korea	2006	2014	-	-	HBV infected	South Korea	5-10-HCC/PLC/liver cancer	Sex ,Age ,ALT ,HBeAg ,Liver stiffness
10.1136/gutjal-2014-309999	CU-HCC	V	External	-	-	-	-	-	HBV infected	mixed ethnicities: Asian and no-Asian	<5-HCC/PLC/liver cancer	Age, Albumin, Bilirubin, HBV DNA, Cirrhosis
	REACH-B	V	External	-	-	-	-	-	HBV infected	mixed ethnicities: Asian and no-Asian	<5-HCC/PLC/liver cancer	Sex ,Age , ALT , HBeAg,HBV DNA
	NGM1-HCC	V	External	-	-	-	-	-	HBV infected	mixed ethnicities: Asian and no-Asian	<5-HCC/PLC/liver cancer	-
	NGM2-HCC	V	External	-	-	-	-	-	HBV infected	mixed ethnicities: Asian and no-Asian	<5-HCC/PLC/liver cancer	-
	GAG-HCC	V	External	-	-	-	-	-	HBV infected	mixed ethnicities: Asian and no-Asian	<5-HCC/PLC/liver cancer	Sex, Age ,HBV DNA , Core promoter mutations, Cirrhosis
	GAG-HCC	V	External	-	-	-	-	-	HBV infected	mixed ethnicities: Asian and no-Asian	5-HCC/PLC/liver cancer	Sex, Age ,HBV DNA , Core promoter mutations, Cirrhosis
10.1111/jvh.12727	PAGE-B	V	External	-	1985	2012	-	-	HBV infected	Netherlands	10-SLD/advanced liver disease/cirrhosis/liver death	Platelets, gender, age
	REACH-B	V	External	-	1985	2012	-	-	HBV infected	Netherlands	10-SLD/advanced liver disease/cirrhosis/liver death	Gender, age, ALT, HBeAg status, hepatitis B virus(HBV)DNA load(copies/mL)
	FIB-4	V	External	-	1985	2012	-	-	HBV infected	Netherlands	10-SLD/advanced liver disease/cirrhosis/liver death	Platelets, age, aspartate aminotransferase (AST), ALT
	Log APRI	V	External	-	1985	2012	-	-	HBV infected	Netherlands	10-SLD/advanced liver disease/cirrhosis/liver death	Platelets, AST
	PAGE-B + Ishak	V	External	-	1985	2012	-	-	HBV infected	Netherlands	10-SLD/advanced liver disease/cirrhosis/liver death	Gender, age, ALT, HBeAg status, hepatitis B virus(HBV)DNA load(copies/mL)
	GAG-HCC	V	External	-	1985	2012	-	-	HBV infected	Netherlands	10-SLD/advanced liver disease/cirrhosis/liver death	Gender, age, HBV DNA load(copies/mL), cirrhosis(US+)
	CU-HCC	V	External	-	1985	2012	-	-	HBV infected	Netherlands	10-SLD/advanced liver disease/cirrhosis/liver death	Age, albumin, bilirubin, HBV DNA load(copies/mL), cirrhosis (US+)
	Ishak fibrosis	V	External	-	1985	2012	-	-	HBV infected	Netherlands	10-SLD/advanced liver disease/cirrhosis/liver death	Ishak fibrosis
	PAGE-B	V	External	-	1985	2012	-	-	HBV infected	Netherlands	10-HCC/PLC/liver cancer	Platelets, gender, age
	REACH-B	V	External	-	1985	2012	-	-	HBV infected	Netherlands	10-HCC/PLC/liver cancer	Gender, age, ALT, HBeAg status, hepatitis B virus(HBV)DNA load(copies/mL)
	FIB-4	V	External	-	1985	2012	-	-	HBV infected	Netherlands	10-HCC/PLC/liver cancer	Platelets, age, aspartate aminotransferase (AST), ALT
	Log APRI	V	External	-	1985	2012	-	-	HBV infected	Netherlands	10-HCC/PLC/liver cancer	Platelets, AST
	PAGE-B + Ishak	V	External	-	1985	2012	-	-	HBV infected	Netherlands	10-HCC/PLC/liver cancer	Gender, age, ALT, HBeAg status, hepatitis B virus(HBV)DNA load(copies/mL)
	GAG-HCC	V	External	-	1985	2012	-	-	HBV infected	Netherlands	10-HCC/PLC/liver cancer	Gender, age, HBV DNA load(copies/mL), cirrhosis(US+)
	CU-HCC	V	External	-	1985	2012	-	-	HBV infected	Netherlands	10-HCC/PLC/liver cancer	Age, albumin, bilirubin, HBV DNA load(copies/mL), cirrhosis (US+)
	Ishak fibrosis	V	External	-	1985	2012	-	-	HBV infected	Netherlands	10-HCC/PLC/liver cancer	Ishak fibrosis
10.1136/gutjal-2015-310818	RWS-HCC	D	-	Singapore General Hospital Department of Gastroenterology and Hepatology with ethics approval.	-	-	-	-	HBV infected	Singapore	10-HCC/PLC/liver cancer	age, gender, cirrhosis, serum AFP
	RWS-HCC	V	External	REACH-B cohorts	-	-	-	-	HBV infected	Asia	10-HCC/PLC/liver cancer	age, gender, cirrhosis, serum AFP
	RWS-HCC	V	External	GAG-HCC cohort	-	-	-	-	HBV infected	Asia	10-HCC/PLC/liver cancer	age, gender, cirrhosis, serum AFP
	RWS-HCC	V	External	CU-HCC cohort	-	-	-	-	HBV infected	Asia	10-HCC/PLC/liver cancer	age, gender, cirrhosis, serum AFP
10.1007/s10620-020-06762-w	Liver Volume Index	D	-	CHC Patients	2003	2016	-	-	HCV infected	South Korea	<5-HCC/PLC/liver cancer	Volume Index, cirrhosis, GGT > 80 U/L
	Liver Volume Index	D	-	CHC Patients	2003	2016	-	-	HCV infected	South Korea	5-HCC/PLC/liver cancer	Volume Index, cirrhosis, GGT > 80 U/L
	Liver Volume Index	D	-	CHC Patients	2003	2016	-	-	HCV infected	South Korea	5-10-HCC/PLC/liver cancer	Volume Index, cirrhosis, GGT > 80 U/L
	Liver Volume Index	V	Internal	CHC Patients	2003	2016	-	-	HCV infected	South Korea	<5-HCC/PLC/liver cancer	Volume Index, cirrhosis, GGT > 80 U/L
	Liver Volume Index	V	Internal	CHC Patients	2003	2016	-	-	HCV infected	South Korea	<5-HCC/PLC/liver cancer	Volume Index, cirrhosis, GGT > 80 U/L
	Liver Volume Index	V	Internal	CHC Patients	2003	2016	-	-	HCV infected	South Korea	5-10-HCC/PLC/liver cancer	Volume Index, cirrhosis, GGT > 80 U/L